

Safety and Efficacy of Pembrolizumab Monotherapy in Advanced Gastric and Gastroesophageal Junction Cancer

JAMA Oncology

4, e180013

DOI: [10.1001/jamaoncol.2018.0013](https://doi.org/10.1001/jamaoncol.2018.0013)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 696-713.	7.7	107
2	Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 221-227.	0.8	6
3	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2836-2844.	0.8	459
4	Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?. <i>Journal of Thoracic Disease</i> , 2018, 10, 6407-6411.	0.6	8
5	Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 3583-3616.	1.4	118
6	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1198-1206.	0.6	6
7	The role of third-line chemotherapy in recurrent or metastatic gastric cancer. <i>Medicine (United States)</i> , 2018, 97, 1000000.	0.4	5
8	Role of immunotherapy in kidney cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 325-333.	0.5	7
12	Efficacy prediction of targeted therapy for gastric cancer: The current status (Review). <i>Molecular Medicine Reports</i> , 2018, 18, 1238-1246.	1.1	4
13	New drug developments in metastatic gastric cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880807.	1.4	19
15	The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 610.	1.3	6
16	Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators. <i>Immune Network</i> , 2018, 18, e45.	1.6	10
17	Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 167-174.	1.0	0
18	Pembrolizumab for the treatment of gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1177-1187.	1.1	13
19	Gastric cancer: Basic aspects. <i>Helicobacter</i> , 2018, 23, e12523.	1.6	35
20	9 weeks that matter for patients with gastric cancer. <i>Lancet Oncology</i> , 2018, 19, 1418-1419.	5.1	3
21	Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6525-6537.	1.0	10
22	Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1437-1448.	5.1	345

#	ARTICLE	IF	CITATIONS
23	Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends. <i>Cancer Treatment Reviews</i> , 2018, 71, 32-38.	3.4	11
24	Towards precision medicine: linking genetic and cellular heterogeneity in gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879462.	1.4	15
25	Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. , 2018, 6, 91.		51
26	Pembrolizumab for the first-line treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1015-1021.	1.4	18
27	Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future. <i>Annals of Oncology</i> , 2018, 29, 1377-1385.	0.6	13
28	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1602.	1.8	48
29	Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. <i>Annals of Oncology</i> , 2018, 29, 2052-2060.	0.6	387
30	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878622.	1.4	5
31	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2018, 62, 29-39.	1.7	860
32	The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2079.	1.8	26
33	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2087.	1.8	14
34	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. <i>Biomedicines</i> , 2018, 6, 87.	1.4	8
35	MUC16 Mutations and Prognosis in Gastric Cancer. <i>JAMA Oncology</i> , 2018, 4, 1698.	3.4	4
36	Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed. <i>Annals of Oncology</i> , 2018, 29, 2027-2028.	0.6	10
37	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018, 67, 2056-2067.	6.1	179
38	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	6.3	984
39	Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma. <i>Lancet</i> , The, 2018, 392, 97-98.	6.3	5
40	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. <i>Frontiers in Oncology</i> , 2019, 9, 618.	1.3	9

#	ARTICLE	IF	CITATIONS
41	Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-3.	0.2	1
42	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6160-6169.	3.2	73
43	Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?. <i>British Journal of Cancer</i> , 2019, 121, 278-280.	2.9	22
44	Novel Delivery Systems for Checkpoint Inhibitors. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 74.	0.7	24
45	Case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and a review of immunotherapy in gastroesophageal tumors. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 51-59.	0.3	0
46	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 1195.	3.4	431
47	Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma. <i>Frontiers in Immunology</i> , 2019, 10, 1580.	2.2	45
48	Ramucirumab plus pembrolizumab: can we make the maths work?. <i>Lancet Oncology</i> , The, 2019, 20, 1041-1043.	5.1	1
49	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123.	5.1	193
50	Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. <i>Scientific Reports</i> , 2019, 9, 10526.	1.6	9
51	Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985999.	1.4	13
52	Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1779-1790.	2.0	10
53	Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 761-771.	1.6	18
54	Road map to best practices. , 2019, , 241-273.		2
55	Gastric Cancer in the Era of Immune Checkpoint Blockade. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	23
56	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5452.	1.8	53
58	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 846-854.	3.2	90
59	Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer. <i>Cancer Communications</i> , 2019, 39, 74.	3.7	24

#	ARTICLE	IF	CITATIONS
60	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
61	Targeted and novel therapy in advanced gastric cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 25.	2.0	53
62	The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. , 2019, 7, 278.		586
63	Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 158.	1.8	29
64	Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status. <i>Oncology Letters</i> , 2019, 18, 1775-1785.	0.8	8
65	When Inhibitor MET Biomarker: Postmortem or Initium Novum?. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	3
66	Gastric cancer: Translating novels concepts into clinical practice. <i>Cancer Treatment Reviews</i> , 2019, 79, 101889.	3.4	60
67	Late-line treatment in metastatic gastric cancer: today and tomorrow. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986752.	1.4	37
68	The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986976.	1.4	31
69	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3392-3400.	0.8	293
70	ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1597-1603.	2.0	16
71	Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 63-63.	1.5	12
72	Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 59-59.	1.5	21
73	Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 100.	1.3	26
74	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4705.	1.8	48
75	Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies. <i>Pharmacoeconomics</i> , 2019, 37, 1537-1551.	1.7	12
76	<p>Enumeration And Characterization Of Circulating Tumor Cells And Its Application In Advanced Gastric Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7887-7896.	1.0	17
77	Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 105-109.	0.7	5

#	ARTICLE	IF	CITATIONS
78	The promising role of monoclonal antibodies for gastric cancer treatment. <i>Immunotherapy</i> , 2019, 11, 347-364.	1.0	10
79	Implementing TMB measurement in clinical practice: considerations on assay requirements. <i>ESMO Open</i> , 2019, 4, e000442.	2.0	257
80	Application of positron emission tomography imaging to personalize esophagogastric cancer care. <i>Cancer</i> , 2019, 125, 1214-1217.	2.0	4
81	Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 1522.	1.6	23
82	Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. , 2019, 7, 24.		114
83	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. <i>Clinical Science</i> , 2019, 133, 181-193.	1.8	51
84	Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cancer. <i>Annals of Oncology</i> , 2019, 30, 351-352.	0.6	3
85	<p>Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4297-4312.	0.9	47
86	Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. <i>Journal of Cancer</i> , 2019, 10, 1764-1771.	1.2	11
87	Immunohistochemistry-Enabled Precision Medicine. <i>Cancer Treatment and Research</i> , 2019, 178, 111-135.	0.2	5
88	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. <i>Annals of Oncology</i> , 2019, 30, 1448-1459.	0.6	146
89	Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. <i>Diagnostic Pathology</i> , 2019, 14, 62.	0.9	4
90	A good start of immunotherapy in esophageal cancer. <i>Cancer Medicine</i> , 2019, 8, 4519-4526.	1.3	67
91	Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. <i>Annals of Oncology</i> , 2019, 30, 1479-1486.	0.6	336
92	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 227-240.	1.1	50
93	Recent advances in the study of regulatory T cells in gastric cancer. <i>International Immunopharmacology</i> , 2019, 73, 560-567.	1.7	27
94	Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy. <i>Current Topics in Microbiology and Immunology</i> , 2019, 421, 319-359.	0.7	29
95	Application of PD-1 Blockade in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 661-674.	1.9	333

#	ARTICLE	IF	CITATIONS
96	Optimizing Therapies in the Perioperative Management of Gastric Cancer. Current Treatment Options in Oncology, 2019, 20, 57.	1.3	13
97	From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1872, 37-48.	3.3	21
98	Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study. International Journal of Clinical Oncology, 2019, 24, 1197-1203.	1.0	5
99	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 255.	3.5	577
100	Anti-angiogenic therapies for gastric cancer. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 208-217.	0.7	31
101	Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma. Journal of Gastrointestinal Oncology, 2019, 10, 367-372.	0.6	5
102	Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 3-10.	1.8	173
103	Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. Journal of Hematology and Oncology, 2019, 12, 50.	6.9	44
104	Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 237-247.	1.8	18
105	Immunotherapy in Older Adults: A Checkpoint to Palliation?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e110-e120.	1.8	11
106	Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncology, 2019, 15, 2073-2082.	1.1	55
107	Keeping Checkpoint Inhibitors in Check. JAMA Network Open, 2019, 2, e192546.	2.8	9
108	Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies. Histopathology, 2019, 75, 526-536.	1.6	17
109	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. BioMed Research International, 2019, 2019, 1-15.	0.9	37
110	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459
111	CheckMate-032 Study: promising efficacy with nivolumab-based immunotherapy in pretreated esophagogastric cancer. Journal of Thoracic Disease, 2019, 11, S394-S395.	0.6	6
112	Immuno-checkpoint inhibitors in metastatic esophago-gastric cancer. Journal of Thoracic Disease, 2019, 11, S376-S380.	0.6	1
113	PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival. Pathology Research and Practice, 2019, 215, 152402.	1.0	11

#	ARTICLE	IF	CITATIONS
114	Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. <i>Oncolmmunology</i> , 2019, 8, e1581547.	2.1	69
115	The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancerâ€™”Ways of Enhancing Immunotherapy Action. <i>Cancers</i> , 2019, 11, 533.	1.7	37
116	Immune checkpoint inhibitors in esophagogastric cancer: still a long way to go. <i>Journal of Thoracic Disease</i> , 2019, 11, 351-353.	0.6	0
117	ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. <i>Annals of Oncology</i> , 2019, 30, 1232-1243.	0.6	614
118	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526
119	Prognostic role of ARID1A negative expression in gastric cancer. <i>Scientific Reports</i> , 2019, 9, 6769.	1.6	34
120	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 42.	6.9	58
121	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52
122	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. <i>Cancer Communications</i> , 2019, 39, 1-31.	3.7	418
123	<i>JAMA Oncology</i> â€™”The Year in Review, 2018. <i>JAMA Oncology</i> , 2019, 5, 609.	3.4	0
124	Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. <i>Cancer Immunology Research</i> , 2019, 7, 737-750.	1.6	691
125	Omitted Disclosures of Potential Conflicts of Interest in Articles Published in <i>JAMA Oncology</i>. <i>JAMA Oncology</i> , 2019, 5, 578.	3.4	2
126	Expression of PD-L1 and PD-1 in Chemoradiotherapy-NaÃ¼ve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. <i>Frontiers in Oncology</i> , 2019, 9, 136.	1.3	36
128	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837.	2.7	181
130	Predictive markers in gastric cancer immunotherapy treatmentâ€™”are we there yet?. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 4-4.	1.5	2
131	How to better select patients with advanced gastric cancer for immunotherapy. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 6-6.	1.5	8
132	Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156.	3.5	170
133	Optimal management of gastroesophageal junction cancer. <i>Cancer</i> , 2019, 125, 1990-2001.	2.0	29

#	ARTICLE	IF	CITATIONS
134	The path of an esophageal carcinoma patient from curative to palliative treatment. Memo - Magazine of European Medical Oncology, 2019, 12, 60-62.	0.3	1
135	Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. Journal of Gastric Cancer, 2019, 19, 1.	0.9	328
136	Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. Frontiers of Medicine, 2019, 13, 12-23.	1.5	14
137	Late-onset isolated adrenocorticotrophic hormone deficiency caused by nivolumab: a case report. BMC Endocrine Disorders, 2019, 19, 25.	0.9	27
138	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
139	Immunotherapeutic advances in gastrointestinal malignancies. Npj Precision Oncology, 2019, 3, 4.	2.3	16
140	Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. International Journal of Cancer, 2019, 145, 916-926.	2.3	72
141	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in Cell Biology, 2019, 29, 396-416.	3.6	66
142	KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncology, 2019, 15, 1057-1066.	1.1	132
143	Immunotherapy in Esophagogastric Adenocarcinoma. Visceral Medicine, 2019, 35, 12-16.	0.5	3
144	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncology, 2019, 15, 943-952.	1.1	133
145	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 421-432.	1.4	45
146	Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. Modern Pathology, 2019, 32, 929-942.	2.9	67
147	DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology, 2019, 156, 890-903.	0.6	48
148	How I treat gastric adenocarcinoma. ESMO Open, 2019, 4, e000521.	2.0	16
149	PD-1 Inhibitors in the Advanced Esophageal Cancer. Frontiers in Pharmacology, 2019, 10, 1418.	1.6	22
150	Essential updates 2017/2018: Recent topics in the treatment and research of gastric cancer in Japan. Annals of Gastroenterological Surgery, 2019, 3, 581-591.	1.2	34
151	Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell, 2019, 179, 1177-1190.e13.	13.5	259

#	ARTICLE	IF	CITATIONS
152	Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. , 2019, 7, 306.		642
153	Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomedical Journal, 2019, 42, 299-306.	1.4	62
154	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2019, 629, xxi-xl.	0.4	1
155	Reliability of PD-L1 assays using small tissue samples compared with surgical specimens. Medicine (United States), 2019, 98, e14972.	0.4	15
156	Early recognition of anorexia through patient-generated assessment predicts survival in patients with oesophagogastric cancer. PLoS ONE, 2019, 14, e0224540.	1.1	13
157	Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical. Journal of Thoracic Disease, 2019, 11, S1855-S1860.	0.6	1
158	The immune landscape of esophageal cancer. Cancer Communications, 2019, 39, 79.	3.7	142
159	Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. Cancer Discovery, 2019, 9, 1656-1672.	7.7	37
160	The emerging role of immunotherapy for esophageal cancer. Current Opinion in Gastroenterology, 2019, 35, 337-343.	1.0	39
161	Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype. American Journal of Surgical Pathology, 2019, 43, 851-860.	2.1	47
162	Effect of Yiqi Huayu Jiedu decoction on stages II and III gastric cancer. Medicine (United States), 2019, 98, e17875.	0.4	21
163	Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Medicine (United States), 2019, 98, e18054.	0.4	26
164	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 699-714.	0.6	36
165	The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective. Journal of Oncology, 2019, 2019, 1-22.	0.6	10
166	Acquired CTNNB1 Mutation Drives Immune Checkpoint Inhibitor-Associated Acquired Resistance in a Microsatellite Instability-High Gastroesophageal Adenocarcinoma With Brain Metastases. JCO Precision Oncology, 2019, 3, 1-6.	1.5	3
167	Predictive potential and need for standardization of PD-L1 immunohistochemistry. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 475-484.	1.4	32
168	The roles of PD-L1/PD-L1 and its signalling pathway in gastrointestinal tract cancers. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 3-10.	0.9	12
169	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2

#	ARTICLE	IF	CITATIONS
170	From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 13.	1.8	111
171	Fates of CD8+ T cells in Tumor Microenvironment. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 1-13.	1.9	321
172	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. <i>Cancer Treatment Reviews</i> , 2019, 73, 31-40.	3.4	15
173	Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer. <i>Drugs</i> , 2019, 79, 1-10.	4.9	18
174	Is front-line checkpoint blockade ATTRACTIVE in advanced gastric cancer?. <i>Annals of Oncology</i> , 2019, 30, 159-161.	0.6	6
175	Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). <i>Annals of Oncology</i> , 2019, 30, 250-258.	0.6	230
176	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. <i>Annals of Oncology</i> , 2019, 30, 44-56.	0.6	1,742
177	Immunotherapy in advanced gastric cancer, is it the future?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 25-32.	2.0	97
178	Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. <i>Oncologist</i> , 2019, 24, 475-482.	1.9	23
179	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMOâ€ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 34-43.	0.6	166
180	Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?. <i>Drugs and Aging</i> , 2019, 36, 1-11.	1.3	10
181	Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. <i>Cancer Letters</i> , 2019, 442, 279-286.	3.2	34
182	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1479-1482.	0.5	10
183	Identification of discrepancy between CTLA4 expression and CTLA4 activation in gastric cancer. <i>Immunopharmacology and Immunotoxicology</i> , 2019, 41, 386-393.	1.1	27
184	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMOâ€ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 19-33.	0.6	165
185	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 106-114.	1.3	41
187	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 793-802.	2.7	124
188	Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. <i>Annals of Oncology</i> , 2019, 30, 424-430.	0.6	44

#	ARTICLE	IF	CITATIONS
189	Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. <i>Clinical Cancer Research</i> , 2019, 25, 515-523.	3.2	354
190	Polymorphism of the programmed death ligand 1 gene is associated with its protein expression and prognosis in gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1201-1207.	1.4	25
191	Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. <i>Future Oncology</i> , 2019, 15, 567-577.	1.1	20
192	Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 357-366.	0.9	9
193	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i> , 2019, 22, 344-354.	2.7	60
194	Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. <i>Cancer</i> , 2019, 125, 742-749.	2.0	55
195	Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. <i>Gastric Cancer</i> , 2019, 22, 817-827.	2.7	42
196	Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 1494-1504.	3.2	45
197	Metal Drugs and the Anticancer Immune Response. <i>Chemical Reviews</i> , 2019, 119, 1519-1624.	23.0	237
198	Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 12-22.	1.5	11
199	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	2.7	45
200	The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 211-222.	0.7	13
201	Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 611-619.	0.6	13
202	Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 32-38.e3.	1.0	16
203	Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 133-141.	2.7	15
204	Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 112-115.	1.4	47
205	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. <i>Gastric Cancer</i> , 2020, 23, 73-81.	2.7	75
206	Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 95-104.	2.7	78

#	ARTICLE	IF	CITATIONS
207	Molecular profiling in gastroesophageal cancerâ€”clinical routine and future perspective. Memo - Magazine of European Medical Oncology, 2020, 13, 440-444.	0.3	3
208	Lack of Lymphocyte Recovery After Esophagectomy Predicts Overall and Recurrence-Free Survival. Journal of Surgical Research, 2020, 246, 379-383.	0.8	1
209	PD-1 and PD-L1 inhibitors in oesophago-gastric cancers. Cancer Letters, 2020, 469, 142-150.	3.2	34
210	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. Journal of Cancer, 2020, 11, 41-50.	1.2	3
211	Trifluridine/tipiracil for the treatment of metastatic gastric cancer. Expert Review of Gastroenterology and Hepatology, 2020, 14, 65-70.	1.4	7
212	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer, 2020, 23, 510-519.	2.7	155
213	PD-L1 expression in gastroesophageal dysplastic lesions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 151-156.	1.4	24
214	Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. Digestive and Liver Disease, 2020, 52, 347-350.	0.4	2
215	Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes. Cancer Treatment Reviews, 2020, 84, 101950.	3.4	19
216	Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. Journal of Clinical Oncology, 2020, 38, 472-479.	0.8	10
217	Esophageal carcinoma: Towards targeted therapies. Cellular Oncology (Dordrecht), 2020, 43, 195-209.	2.1	99
218	Identifying Predictive Factors of Recurrence after Radical Resection in Gastric Cancer by RNA Immune-oncology Panel. Journal of Cancer, 2020, 11, 638-647.	1.2	9
219	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist, 2020, 25, e398-e404.	1.9	10
220	Impact of PDâ€1 expression and human papillomavirus status in antiâ€PD1/PDL1 immunotherapy for head and neck squamous cell carcinomaâ€”Systematic review and metaâ€analysis. Head and Neck, 2020, 42, 774-786.	0.9	52
221	Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer. Journal of Comparative Effectiveness Research, 2020, 9, 103-114.	0.6	5
222	Clinical case of the neoadjuvant treatment with nivolumab in a patient with microsatellite unstable (MSI-H) locally advanced gastric cancer. BMJ Case Reports, 2020, 13, e236144.	0.2	5
223	Complete Response in a Patient With Chemorefractory <i>EGFR</i>-Amplified, PD-L1â€Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Antiâ€PD-1 Monoclonal Antibody Therapy. JCO Precision Oncology, 2020, 4, 1180-1186.	1.5	6
224	Revisiting<i>MET</i>: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic,<i>MET</i>-Amplified Esophagogastric Cancers. Oncologist, 2020, 25, e1691-e1700.	1.9	1

#	ARTICLE	IF	CITATIONS
225	Identification of TYROBP and C1QB as Two Novel Key Genes With Prognostic Value in Gastric Cancer by Network Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1765.	1.3	27
226	Systemic therapy for advanced gastroesophageal cancers: progress and pitfalls. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 53-53.	1.5	6
227	Is ramucirumab still the only second-line treatment in metastatic gastric cancer?. <i>Pharmacogenomics</i> , 2020, 21, 1203-1206.	0.6	1
228	Tackling diversity within diversity. <i>Annals of Oncology</i> , 2020, 31, 970-972.	0.6	1
229	Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. <i>Gastric Cancer</i> , 2021, 24, 457-466.	2.7	34
230	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. <i>Journal of Clinical Medicine</i> , 2020, 9, 3049.	1.0	12
231	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8
232	HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. , 2020, 8, e001279.		11
233	The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. <i>Cancer Biology and Medicine</i> , 2020, 17, 1002-1013.	1.4	18
234	Sarcomas: Immune biomarker expression and checkpoint inhibitor trials. <i>Cancer Treatment Reviews</i> , 2020, 91, 102115.	3.4	48
235	Predictive molecular markers in the era of immunotherapy. <i>Journal of Pancreatology</i> , 2020, 3, 132-138.	0.3	5
236	N6-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer. <i>Cell Death and Disease</i> , 2020, 11, 836.	2.7	50
237	Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?. <i>Frontiers in Oncology</i> , 2020, 10, 912.	1.3	6
238	Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110504.	2.5	26
239	Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3620-e3627.	1.8	24
240	Postoperative radiotherapy for laryngeal cancer. The prognostic role of programmed death-ligand 1: An immune microenvironment-based cluster analysis. <i>Pathology Research and Practice</i> , 2020, 216, 153120.	1.0	12
241	Immunotherapy in Gastrointestinal Cancers. <i>Visceral Medicine</i> , 2020, 36, 231-237.	0.5	7
242	Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 369-378.	1.2	10

#	ARTICLE	IF	CITATIONS
243	<p>Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review</p>. OncoTargets and Therapy, 2020, Volume 13, 11637-11644.	1.0	7
244	Tumor-infiltrating podoplanin ⁺ cells in gastric cancer: clinical outcomes and association with immune contexture. Oncoimmunology, 2020, 9, 1845038.	2.1	7
245	MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101574.	0.7	15
246	Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers. Innovation(China), 2020, 1, 100041.	5.2	31
247	<p>MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT</p>. Cancer Management and Research, 2020, Volume 12, 12215-12223.	0.9	20
248	<p>Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma</p>. Cancer Management and Research, 2020, Volume 12, 11113-11119.	0.9	16
249	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers, 2020, 12, 3285.	1.7	85
250	Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094237.	1.4	7
251	Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. Journal of Clinical Medicine, 2020, 9, 2533.	1.0	15
252	Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer. Translational Cancer Research, 2020, 9, 2434-2448.	0.4	2
253	Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidine. Expert Opinion on Drug Safety, 2020, 19, 1063-1068.	1.0	1
254	Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses. BMC Cancer, 2020, 20, 684.	1.1	9
255	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Frontiers in Cell and Developmental Biology, 2020, 8, 672.	1.8	205
256	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093761.	1.4	78
257	Targeted Therapies in Advanced Gastric Cancer. Current Treatment Options in Oncology, 2020, 21, 70.	1.3	133
258	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treatment Reviews, 2020, 89, 102084.	3.4	61
259	Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer. Frontiers in Oncology, 2020, 10, 1312.	1.3	14
260	High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Scientific Reports, 2020, 10, 12348.	1.6	48

#	ARTICLE	IF	CITATIONS
261	From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancersâ€”A Multidisciplinary Perspective. <i>Cancers</i> , 2020, 12, 2105.	1.7	6
262	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. <i>Experimental Hematology and Oncology</i> , 2020, 9, 17.	2.0	21
263	Immuno-oncology for esophageal cancer. <i>Future Oncology</i> , 2020, 16, 2673-2681.	1.1	16
264	Targeting the immune milieu in gastrointestinal cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 909-926.	2.3	7
265	Different patterns of treatmentâ€”related adverse events of programmed cell deathâ€”1 and its ligandâ€”1 inhibitors in different cancer types: A metaâ€”analysis and systemic review of clinical trials. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e160-e178.	0.7	6
266	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2020, 10, 1842-1853.	7.7	179
267	Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. <i>BMC Cancer</i> , 2020, 20, 760.	1.1	43
268	Role of Immunotherapy in Advanced Gastroesophageal Cancer. <i>Current Oncology Reports</i> , 2020, 22, 112.	1.8	5
270	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. <i>Cancers</i> , 2020, 12, 2985.	1.7	21
271	Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1039-1048.	1.4	12
272	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	1.2	7
273	Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. <i>ESMO Open</i> , 2020, 5, e000775.	2.0	22
274	Efficacy of immuneâ€”checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and metaâ€”analysis. <i>Cancer Medicine</i> , 2020, 9, 7613-7625.	1.3	12
275	Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients. <i>Scientific Reports</i> , 2020, 10, 14293.	1.6	18
276	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1571.	3.4	611
277	Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. <i>Scientific Reports</i> , 2020, 10, 14470.	1.6	11
278	Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer. <i>Journal of Oncology</i> , 2020, 2020, 1-14.	0.6	5
279	Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer. <i>British Journal of Cancer</i> , 2020, 123, 1625-1632.	2.9	15

#	ARTICLE	IF	CITATIONS
280	Gastric cancer. <i>Lancet</i> , The, 2020, 396, 635-648.	6.3	2,084
281	Mucinous gastric adenocarcinoma: A good candidate for immune therapy?. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 624-625.	0.6	1
282	Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated. <i>Cancer</i> , 2020, 126, 4788-4799.	2.0	14
283	The Crosstalk between Microbiome and Immune Response in Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6586.	1.8	49
284	Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. <i>Cancers</i> , 2020, 12, 2598.	1.7	11
285	Gastric cancer: a comprehensive review of current and future treatment strategies. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 1179-1203.	2.7	311
286	<p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3625-3649.	2.0	80
287	<p>Clinical Evaluation of the Safety and Efficacy of Trifluridine/Tipiracil in the Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7459-7465.	1.0	5
288	Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. <i>ESMO Open</i> , 2020, 5, e000791.	2.0	25
289	Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 6453-6463.	3.2	92
290	LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1. <i>Cancer Cell International</i> , 2020, 20, 394.	1.8	53
291	Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094877.	1.4	45
292	The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer. <i>Cancers</i> , 2020, 12, 2318.	1.7	18
293	Overview of Epsteinâ€Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9400.	1.8	12
294	Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing. <i>Gastrointestinal Disorders</i> , 2020, 2, 341-352.	0.4	7
295	Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020. <i>Annals of Translational Medicine</i> , 2020, 8, 1109-1109.	0.7	6
296	Esophageal cancer in Aleppo, Syria 2010â€2020: a rare cancer in a war zone. <i>Annals of Translational Medicine</i> , 2020, 8, 1105-1105.	0.7	0
297	The effect of intestinal flora on immune checkpoint inhibitors in tumor treatment: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1097-1097.	0.7	3

#	ARTICLE	IF	CITATIONS
298	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 1808-1825.	7.7	388
299	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. <i>BioDrugs</i> , 2020, 34, 749-762.	2.2	5
300	Recent Developments of Systemic Chemotherapy for Gastric Cancer. <i>Cancers</i> , 2020, 12, 1100.	1.7	31
301	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020, 25, 803-809.	1.9	26
302	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 821-831.	5.1	243
303	Immunotherapy for esophageal cancer: a 2019 update. <i>Immunotherapy</i> , 2020, 12, 203-218.	1.0	30
304	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
305	TGFB2 serves as a link between epithelial-mesenchymal transition and tumor mutation burden in gastric cancer. <i>International Immunopharmacology</i> , 2020, 84, 106532.	1.7	25
306	Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 513.	1.3	3
307	Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. <i>Cancers</i> , 2020, 12, 1168.	1.7	13
308	Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019. <i>Hematological Oncology</i> , 2020, 38, 565-575.	0.8	22
309	PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study. <i>Pathology and Oncology Research</i> , 2020, 26, 2225-2235.	0.9	15
310	High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas. <i>Diagnostic Pathology</i> , 2020, 15, 50.	0.9	34
311	Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 55-55.	1.5	29
312	A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies. <i>Advances in Therapy</i> , 2020, 37, 2853-2864.	1.3	6
313	Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. <i>Annals of Oncology</i> , 2020, 31, 1011-1020.	0.6	95
314	MSI and EBV Positive Gastric Cancer's Subgroups and Their Link with Novel Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1427.	1.0	55
315	Targeting DNA Repair to Drive Immune Responses: It's Time to Reconsider the Strategy for Clinical Translation. <i>Clinical Cancer Research</i> , 2020, 26, 2452-2456.	3.2	10

#	ARTICLE	IF	CITATIONS
316	Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis. <i>Frontiers in Medicine</i> , 2020, 7, 144.	1.2	15
317	The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 639-644.	1.9	41
318	Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. <i>JCO Precision Oncology</i> , 2020, 4, 514-519.	1.5	1
319	Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors. , 2020, 8, e000154.		23
320	Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e275-e291.	1.8	32
321	Current status of immune checkpoint inhibitors for gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 565-578.	2.7	133
322	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2419-2430.	13.9	681
323	Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1057-1065.	5.1	160
324	Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections. <i>Cancer Cell International</i> , 2020, 20, 186.	1.8	24
325	Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO) Tj ETQq1 1 0.784314zgBT /Over		
326	Precision medicine for gastrointestinal cancers: a conference report. <i>Future Science OA</i> , 2020, 6, FSO478.	0.9	2
327	Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 763.	1.3	32
328	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
329	Finding the hot spot: identifying immune sensitive gastrointestinal tumors. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 48-48.	1.5	6
330	Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. , 2020, 8, e000665.		8
331	The Clinicopathological Features and Genetic Alterations in Epsteinâ€‘Barr Virus-Associated Gastric Cancer Patients after Curative Surgery. <i>Cancers</i> , 2020, 12, 1517.	1.7	24
332	Microbiome and cancer treatment: Are we ready to apply in clinics?. <i>Progress in Molecular Biology and Translational Science</i> , 2020, 171, 301-308.	0.9	9
333	The Cancer-Immune Set Point in Oesophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 891.	1.3	15

#	ARTICLE	IF	CITATIONS
334	Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma. <i>Oral Oncology</i> , 2020, 108, 104836.	0.8	22
335	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70.	1.8	11
336	Maintenance treatment in advanced HER2-negative gastric cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 2206-2212.	1.2	10
337	Assessing Outcomes of Patients Treated With Re-Irradiation Utilizing Proton Pencil-Beam Scanning for Primary or Recurrent Malignancies of the Esophagus and Gastroesophageal Junction. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1054-1064.	0.5	13
338	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. , 2020, 8, e000437.		86
339	Cautious Optimism—The Current Role of Immunotherapy in Gastrointestinal Cancers. <i>Current Oncology</i> , 2020, 27, 59-68.	0.9	4
340	Integrated immune gene expression signature and molecular classification in gastric cancer: New insights. <i>Journal of Leukocyte Biology</i> , 2020, 108, 633-646.	1.5	26
341	Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer. <i>British Journal of Cancer</i> , 2020, 122, 1399-1408.	2.9	6
342	Global updates in the treatment of gastric cancer: a systematic review. Part 1: staging, classification and surgical treatment. <i>Updates in Surgery</i> , 2020, 72, 341-353.	0.9	23
343	Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1751-1756.	1.0	9
344	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 635, xix-xxxviii.	0.4	0
345	Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1658.	1.8	22
346	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
347	Gastric Cancer in Young Adults: A Different Clinical Entity from Carcinogenesis to Prognosis. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-13.	0.7	36
348	Emerging Role of Circulating Tumor Cells in Gastric Cancer. <i>Cancers</i> , 2020, 12, 695.	1.7	30
349	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, xvii-xxxvi.	0.4	0
350	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2418-2426.	0.8	55
351	Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. <i>British Journal of Cancer</i> , 2020, 123, 965-972.	2.9	53

#	ARTICLE	IF	CITATIONS
352	Review of survival, safety, and clinical outcomes in HER2+ metastatic gastric cancer following the administration of trastuzumab. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100189.	0.7	3
353	Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study. <i>Lung Cancer</i> , 2020, 147, 21-25.	0.9	10
354	Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093518.	1.4	6
355	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€“05): a single-arm, phase 1bâ€“2 trial. <i>Lancet Oncology</i> , 2020, 21, 1066-1076.	5.1	130
356	A phase I study of toripalimab, an antiâ€“PDâ€“1 antibody, in patients with refractory malignant solid tumors. <i>Cancer Communications</i> , 2020, 40, 345-354.	3.7	30
357	Metaâ€“analysis of immuneâ€“related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	0.8	40
358	Emerging precision therapies for gastric cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 299-311.	0.4	1
359	Pembrolizumab for the treatment of esophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1143-1150.	1.4	14
360	DC-CIK as a widely applicable cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 601-607.	1.4	28
361	Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. <i>Oncologist</i> , 2020, 25, 669-679.	1.9	30
362	High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. <i>Pathology Research and Practice</i> , 2020, 216, 152881.	1.0	67
363	Esophageal, gastric cancer and immunotherapy: small steps in the right direction?. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 9-9.	1.5	42
364	Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1057-1069.	2.0	31
365	Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 401-411.	1.5	10
366	VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or Tj ETQq0 0 0 ngBT /Overlock 10 Tf		
367	Normalization Cancer Immunotherapy for Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1134-1142.	0.3	13
368	Current status of immunotherapy in gastrointestinal malignancies. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 542-555.	0.2	5
369	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 631, xxiii-xlii.	0.4	1

#	ARTICLE	IF	CITATIONS
370	Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 448.	1.8	6
371	Baseline derived neutrophil-to-lymphocyte ratio as a prognostic biomarker for non-colorectal gastrointestinal cancer patients treated with immune checkpoint blockade. <i>Clinical Immunology</i> , 2020, 212, 108345.	1.4	18
372	SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 236-244.	1.2	28
373	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 182.	1.7	74
374	Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. <i>Gastric Cancer</i> , 2020, 23, 579-590.	2.7	16
375	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 632, xxiii-xlii.	0.4	0
376	New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?. <i>Cancers</i> , 2020, 12, 301.	1.7	7
377	Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). <i>Journal of Clinical Oncology</i> , 2020, 38, 2053-2061.	0.8	469
378	5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 492.	1.3	33
379	Next generation sequencing in gastric or gastroesophageal adenocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 56-56.	1.5	5
380	A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. <i>JAMA Oncology</i> , 2020, 6, 888.	3.4	293
381	Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer. <i>Cancer Cell International</i> , 2020, 20, 92.	1.8	38
382	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. <i>Cancers</i> , 2020, 12, 738.	1.7	826
383	Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study. <i>Journal of Immunotherapy</i> , 2020, 43, 139-144.	1.2	61
384	The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 604.	2.2	51
385	Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 935.	1.0	6
386	MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. <i>Cancer Treatment Reviews</i> , 2020, 86, 102024.	3.4	90
387	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 314.	1.3	62

#	ARTICLE	IF	CITATIONS
388	Safety and efficacy of toripalimab in advanced gastric cancer: A new clinical trial bringing hope for immunotherapy in gastric cancer. <i>Cancer Communications</i> , 2020, 40, 194-196.	3.7	8
389	Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients. <i>Targeted Oncology</i> , 2020, 15, 203-209.	1.7	3
390	Global updates in the treatment of gastric cancer: a systematic review. Part 2: perioperative management, multimodal therapies, new technologies, standardization of the surgical treatment and educational aspects. <i>Updates in Surgery</i> , 2020, 72, 355-378.	0.9	16
391	Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152947.	1.0	11
392	Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF β 2 and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3202-3210.	3.2	24
393	The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3784-3790.	3.2	49
394	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , 2020, 25, 780-786.	1.9	14
395	Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate. <i>Cancers</i> , 2020, 12, 873.	1.7	34
396	Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes. <i>Journal of the National Cancer Institute</i> , 2021, 113, 88-98.	3.0	15
397	A review of glioblastoma immunotherapy. <i>Journal of Neuro-Oncology</i> , 2021, 151, 41-53.	1.4	159
398	Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer. <i>Briefings in Bioinformatics</i> , 2021, 22, 2020-2031.	3.2	99
399	CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 142-148.	2.8	5
400	Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 123-132.	0.7	10
401	PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?. <i>Journal of Gene Medicine</i> , 2021, 23, e3294.	1.4	14
402	A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 337-348.	2.0	18
403	A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604). <i>Gastric Cancer</i> , 2021, 24, 190-196.	2.7	10
404	Multivisceral Resection for Locally Advanced Gastric Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 609-622.	0.9	10
405	The Evolving Management of Peritoneal Surface Malignancies. <i>Current Problems in Surgery</i> , 2021, 58, 100860.	0.6	2

#	ARTICLE	IF	CITATIONS
406	The changing face of gastric cancer: epidemiologic trends and advances in novel therapies. <i>Cancer Gene Therapy</i> , 2021, 28, 390-399.	2.2	23
407	Immunotherapy in gastroesophageal cancers: Current state and future directions. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 395-404.	0.5	2
408	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , 2021, 17, 491-501.	1.1	117
409	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , 2021, 39, 966-977.	0.8	122
410	Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 694-707.	5.7	56
411	Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker. <i>AAPS Journal</i> , 2021, 23, 5.	2.2	22
412	Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer. <i>Annals of Diagnostic Pathology</i> , 2021, 50, 151657.	0.6	21
413	MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 1155-1164.	1.1	64
414	Current status of immunotherapy for advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 20-27.	0.6	43
415	Immune response drives outcomes in prostate cancer: implications for immunotherapy. <i>Molecular Oncology</i> , 2021, 15, 1358-1375.	2.1	48
416	Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities. <i>Cancer Medicine</i> , 2021, 10, 659-674.	1.3	2
417	Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. <i>British Journal of Cancer</i> , 2021, 124, 595-603.	2.9	24
418	<sc>Lymphocyte activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epstein-Barr virus positive and MLH1 defective gastric cancer patients</sc>. <i>International Journal of Cancer</i> , 2021, 148, 759-768.	2.3	15
419	Early change in peripheral CD4 ⁺ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer. <i>Immunotherapy</i> , 2021, 13, 55-66.	1.0	15
421	PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. <i>Gastroenterology</i> , 2021, 160, 781-796.	0.6	67
422	Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 248-258.	0.6	6
423	Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 327-340.	2.7	13
424	All in the Levels—Programmed Death-Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Patients with Gastrointestinal Cancer. <i>Oncologist</i> , 2021, 26, e186-e188.	1.9	3

#	ARTICLE	IF	CITATIONS
425	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cellular and Molecular Life Sciences, 2021, 78, 867-887.	2.4	9
426	Identification of a novel immune prognostic model in gastric cancer. Clinical and Translational Oncology, 2021, 23, 846-855.	1.2	12
427	Gut microbiota: impacts on gastrointestinal cancer immunotherapy. Gut Microbes, 2021, 13, 1-21.	4.3	33
428	Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer. In Vivo, 2021, 35, 1865-1875.	0.6	4
429	Inestabilidad microsatelital y cáncer gástrico. Revista Colombiana De Cirugia, 2021, 36, 120-131.	0.2	0
430	Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play. International Journal of Molecular Sciences, 2021, 22, 1071.	1.8	8
431	T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival. OncoImmunology, 2021, 10, 1921443.	2.1	14
432	When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer. Journal of Cancer, 2021, 12, 5681-5686.	1.2	0
433	Circulating Tumor Cells in Gastric Cancer. , 2021, , 103-126.		0
434	Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. Gastroenterology Report, 2021, 9, 560-570.	0.6	10
435	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. Pharmaceuticals, 2021, 14, 89.	1.7	9
436	Prognostic role of tumour-infiltrating lymphocytes assessed by H&E-stained section in gastric cancer: a systematic review and meta-analysis. BMJ Open, 2021, 11, e044163.	0.8	15
437	Biomarkers of Esophageal Cancers and Precancerous Lesions. Physiology in Health and Disease, 2021, , 111-153.	0.2	0
438	Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy. Expert Review of Anticancer Therapy, 2021, 21, 535-546.	1.1	9
439	Emerging role of circulating tumor cells in immunotherapy. Theranostics, 2021, 11, 8057-8075.	4.6	19
440	Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. OncoImmunology, 2021, 10, 1915560.	2.1	17
441	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10. Clinical Cancer Research, 2021, 27, 1923-1931.	3.2	53
442	The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. Journal of Hematology and Oncology, 2021, 14, 13.	6.9	49

#	ARTICLE	IF	CITATIONS
443	Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article. <i>Oncology Research and Treatment</i> , 2021, 44, 485-494.	0.8	12
444	Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 37-57.	0.8	3
445	Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592198899.	1.4	17
446	PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 462-466.	0.6	9
447	Systems biology and molecular characterization of subtypes to guide targeted therapies in gastric cancer. , 2021, , 259-288.		0
449	Importance of Systemic Chemotherapy in Advanced Peritoneal Metastasis. , 2021, , 239-253.		0
450	Image-Guided Intratumoral Delivery of Immunotherapeutics in Gastrointestinal Malignancies. <i>Digestive Disease Interventions</i> , 2021, 05, 022-031.	0.3	4
451	Severe colitis induced by pembrolizumab in a patient with advanced hypopharyngeal squamous cell carcinoma: A case report of an immune-related adverse event. <i>Journal of Cancer Research and Practice</i> , 2021, 8, 113.	0.2	1
452	NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 574937.	1.3	29
453	Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma. <i>Pharmaceuticals</i> , 2021, 14, 151.	1.7	18
454	Efficacy and safety of immune checkpoint inhibitors in gastric cancer: a network meta-analysis of well-designed randomized controlled trials. <i>Annals of Translational Medicine</i> , 2021, 9, 290-290.	0.7	5
455	Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer. <i>DNA and Cell Biology</i> , 2021, 40, 405-413.	0.9	5
457	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. <i>Seminars in Cancer Biology</i> , 2022, 84, 89-102.	4.3	21
458	Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virus-Associated Gastric Adenocarcinoma With ERBB2 Amplification. <i>JCO Precision Oncology</i> , 2021, 5, 370-377.	1.5	2
459	Immunotherapeutic advances in gastric cancer. <i>Surgery Today</i> , 2021, 51, 1727-1735.	0.7	14
460	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
461	Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-Cell mediated anti-tumor immunity in an esophageal adenocarcinoma model. <i>Oncotarget</i> , 2021, 12, 292-303.	0.8	20
462	PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study. <i>Pathology Research and Practice</i> , 2021, 218, 153338.	1.0	12

#	ARTICLE	IF	CITATIONS
463	Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2559-2576.	2.0	40
464	Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 612451.	1.8	17
465	Molecular targeted treatment and drug delivery system for gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 973-986.	1.2	18
466	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. <i>Cancers</i> , 2021, 13, 651.	1.7	7
467	Practical prediction model of the clinical response to programmed death-ligand 1 inhibitors in advanced gastric cancer. <i>Experimental and Molecular Medicine</i> , 2021, 53, 223-234.	3.2	12
468	Understanding relevant immune mechanisms in gastrointestinal oncology. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 107815522199286.	0.5	0
469	Immunotherapy of gastric cancer: Past, future perspective and challenges. <i>Pathology Research and Practice</i> , 2021, 218, 153322.	1.0	51
470	Long Non-coding RNA Expression Patterns in Stomach Adenocarcinoma Serve as an Indicator of Tumor Mutation Burden and Are Associated With Tumor-Infiltrating Lymphocytes and Microsatellite Instability. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 618313.	1.8	6
471	Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. <i>Annals of Translational Medicine</i> , 2021, 9, 513-513.	0.7	4
472	<sc>SHRâ€1316</sc>, an <sc>antiâ€PDâ€1</sc> antibody, plus chemotherapy as the firstâ€line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase <sc>2</sc> study. <i>Thoracic Cancer</i> , 2021, 12, 1373-1381.	0.8	15
473	Targeted and immunotherapy in the era of personalised gastric cancer treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101738.	1.0	15
474	Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). <i>Cancers</i> , 2021, 13, 1304.	1.7	2
475	The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2893-2909.	2.0	31
476	Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 650481.	1.3	23
477	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 473-487.	12.5	139
478	Changes in the therapeutic landscape of oesophago-gastric cancers. <i>Current Opinion in Oncology</i> , 2021, 33, 362-367.	1.1	0
479	Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3069-3078.	3.2	60
480	CCL5 production by fibroblasts through a local reninâ€angiotensin system in malignant melanoma affects tumor immune responses. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1993-2001.	1.2	9

#	ARTICLE	IF	CITATIONS
481	Recent advances in immune therapies for gastric cancer. <i>Cancer Gene Therapy</i> , 2021, 28, 924-934.	2.2	16
482	The impact of recent next generation sequencing and the need for a new classification in gastric cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101730.	1.0	18
483	Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. <i>Gastric Cancer</i> , 2021, 24, 970-977.	2.7	5
484	Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 209-217.	3.7	20
485	Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. <i>Gastric Cancer</i> , 2021, 24, 567-576.	2.7	19
486	Outcomes on anti-VEGFR/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. <i>International Journal of Cancer</i> , 2021, 149, 378-386.	2.3	14
487	The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2053-2064.	1.0	12
488	Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 331.	1.1	1
489	Isolated brachioradialis metastasis of gastric adenocarcinoma after R0 resection. <i>World Journal of Surgical Oncology</i> , 2021, 19, 83.	0.8	0
490	Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti-PD-1 Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 638312.	1.8	29
491	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3926-3935.	3.2	55
492	Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1429-1441.	0.9	2
493	Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. <i>AAPS Journal</i> , 2021, 23, 39.	2.2	356
494	The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity. <i>BMC Cancer</i> , 2021, 21, 240.	1.1	14
495	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. <i>Biomedicines</i> , 2021, 9, 318.	1.4	7
496	Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 170-185.	1.8	1
497	Therapeutic applications of the cancer immunoediting hypothesis. <i>Seminars in Cancer Biology</i> , 2022, 78, 63-77.	4.3	29
498	DNA damage response alterations in gastric cancer: knocking down a new wall. <i>Future Oncology</i> , 2021, 17, 865-868.	1.1	21

#	ARTICLE	IF	CITATIONS
499	Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 617335.	1.3	49
500	Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection. <i>Annals of Surgical Oncology</i> , 2021, 28, 7040-7050.	0.7	0
501	Microsatellite instability in Gastric Cancer: Between lights and shadows. <i>Cancer Treatment Reviews</i> , 2021, 95, 102175.	3.4	88
502	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3641-3648.	3.2	32
503	A Low Tumor Mutational Burden and <i>PTEN</i> Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3714-3724.	3.2	61
504	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 562315.	1.3	38
505	Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 825-830.	1.4	6
506	Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2022, 79, 4-17.	4.3	70
507	Challenges and perspectives for immunotherapy in Esophageal cancer: A look to the future (Review). <i>International Journal of Molecular Medicine</i> , 2021, 47, .	1.8	3
508	Epstein-Barr Virus-Associated Gastric Cancer: Old Entity with New Relevance. , 0, , .		1
509	Patterns of immune infiltration in gastric cancer and their clinical significance. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1067-1079.	0.6	3
510	PRODICE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2021, 53, 420-426.	0.4	10
511	Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer. <i>Future Oncology</i> , 2021, 17, 1553-1569.	1.1	9
512	Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond. <i>Cancers</i> , 2021, 13, 1715.	1.7	19
513	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. <i>Cancer Discovery</i> , 2021, 11, 2168-2185.	7.7	105
514	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 650292.	1.3	22
515	How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. <i>Journal of Clinical Medicine</i> , 2021, 10, 1412.	1.0	8
516	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF β 2 and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. <i>Targeted Oncology</i> , 2021, 16, 447-459.	1.7	16

#	ARTICLE	IF	CITATIONS
517	Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma. <i>European Journal of Cancer</i> , 2021, 148, 1-13.	1.3	9
518	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort. <i>Targeted Oncology</i> , 2021, 16, 435-446.	1.7	21
519	Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. <i>Annals of Oncology</i> , 2021, 32, 590-599.	0.6	91
520	PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. <i>Modern Pathology</i> , 2021, 34, 1719-1727.	2.9	48
521	Inflammation-Induced Tumorigenesis and Metastasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5421.	1.8	88
522	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. <i>Npj Precision Oncology</i> , 2021, 5, 36.	2.3	20
523	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
524	Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical Trials. <i>Cancers</i> , 2021, 13, 2614.	1.7	11
525	Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2111113.	2.8	17
526	Evolving treatment paradigms in esophageal cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 903-903.	0.7	9
527	Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 191-207.	3.0	5
528	Administration of fusion cytokines induces tumor regression and systemic antitumor immunity. <i>MedComm</i> , 2021, 2, 256-268.	3.1	4
529	Angiogenesis, programmed death ligand 1 (PD-L1) and immune microenvironment association in laryngeal carcinoma. <i>Pathology</i> , 2021, 53, 844-851.	0.3	7
530	Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 366-390.	0.8	4
531	Immunotherapy for GI Cancers. <i>Advances in Oncology</i> , 2021, 1, 283-295.	0.1	0
532	Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy. <i>Journal of Surgical Research</i> , 2021, 261, 130-138.	0.8	7
533	The Emerging Role of Liquid Biopsy in Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 2108.	1.0	20
534	Intratumoral Foxp3+ROR γ t+ T cell infiltration determines poor prognosis and immunoevasive contexture in gastric cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1-11.	2.0	9

#	ARTICLE	IF	CITATIONS
535	Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.4	1
536	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. <i>Cancers</i> , 2021, 13, 2638.	1.7	32
537	Salvage Treatment Using Anti-“PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma. <i>Oncologist</i> , 2021, 26, 461-464.	1.9	1
538	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1623-1634.	1.4	10
539	A narrative review of combining radiation and immunotherapy in gastroesophageal cancers. <i>Translational Cancer Research</i> , 2021, 10, 2586-2595.	0.4	1
540	Her2-Positive and Microsatellite Instability Status in Gastric Cancer-“Clinicopathological Implications. <i>Diagnostics</i> , 2021, 11, 944.	1.3	15
541	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5123.	1.8	61
542	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-“High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021, 7, 895.	3.4	184
543	The Immune Subtypes and Landscape of Gastric Cancer and to Predict Based on the Whole-Slide Images Using Deep Learning. <i>Frontiers in Immunology</i> , 2021, 12, 685992.	2.2	33
544	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 641428.	1.3	32
546	DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 24, 695-710.	2.3	25
547	PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 648068.	1.3	13
548	Tremellimumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021, 13, 2839.	1.7	31
549	The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 655716.	1.3	13
550	A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 693314.	2.2	10
551	Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor. <i>Frontiers in Oncology</i> , 2021, 11, 589022.	1.3	20
552	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 630-638.	0.5	23
553	Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review. <i>Advances in Therapy</i> , 2021, 38, 3674-3693.	1.3	12

#	ARTICLE	IF	CITATIONS
554	Chemoradiation Therapy as Definitive Treatment of Esophageal Cancer. <i>Surgical Clinics of North America</i> , 2021, 101, 443-451.	0.5	7
555	Immunotherapy in endometrial cancer: rationale, practice and perspectives. <i>Biomarker Research</i> , 2021, 9, 49.	2.8	53
556	Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches. <i>Cancer Treatment Reviews</i> , 2021, 98, 102219.	3.4	4
557	Metabolism-Relevant Molecular Classification Identifies Tumor Immune Microenvironment Characterization and Immunotherapeutic Effect in Cervical Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 624951.	1.6	4
558	Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3983-3989.	1.0	2
559	Comparing immunotherapies to other frequently used treatments of gastric cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1221-1232.	1.3	2
560	Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. <i>Frontiers in Immunology</i> , 2021, 12, 701668.	2.2	13
561	Research status on immunotherapy trials of gastric cancer. <i>World Journal of Clinical Cases</i> , 2021, 9, 5782-5793.	0.3	5
562	Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers. <i>British Journal of Cancer</i> , 2021, 125, 1068-1079.	2.9	23
563	Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity. <i>Vaccines</i> , 2021, 9, 807.	2.1	2
564	KLF7 Promotes Gastric Carcinogenesis Through Regulation of ANTXR1. <i>Cancer Management and Research</i> , 2021, Volume 13, 5547-5557.	0.9	10
565	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2021, 12, 714483.	1.6	9
566	HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study. <i>BMC Surgery</i> , 2021, 21, 308.	0.6	9
567	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. <i>Cancer Communications</i> , 2021, 41, 747-795.	3.7	323
568	Advances in Systemic Therapy for Gastric Cancer. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2021, 31, 607-623.	0.6	11
569	Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1244-1256.	0.9	4
570	Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study. <i>Clinical Cancer Research</i> , 2021, 27, 5141-5150.	3.2	33
571	lncRNAs as Hallmarks for Individualized Treatment of Gastric Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, .	0.9	1

#	ARTICLE	IF	CITATIONS
572	Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. <i>Pharmacogenomics</i> , 2021, 22, 703-726.	0.6	3
573	Complete response to neoadjuvant pembrolizumab and capecitabine in microsatellite stable, Epstein-Barr virus-positive, locally advanced gastric adenocarcinoma: case report. <i>AME Case Reports</i> , 2021, 5, 30-30.	0.2	2
574	Human Leukocyte Antigen Class I Deficiency in Gastric Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1213-1220.	2.1	6
575	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. <i>Oncologist</i> , 2021, 26, e1786-e1799.	1.9	52
576	A Prognostic Signature Constructed by CTHRC1 and LRFN4 in Stomach Adenocarcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 646818.	1.1	4
577	Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. , 2021, 9, e002467.		97
578	TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies. , 2021, 224, 107823.		10
579	Autophagy controls programmed deathâ€ligandâ€1 expression on cancer cells (Review). <i>Biomedical Reports</i> , 2021, 15, 84.	0.9	12
580	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , The, 2021, 398, 759-771.	6.3	642
581	Programmed deathâ€ligand 1 expression in human papillomavirusâ€independent cervical adenocarcinoma and its prognostic significance. <i>Histopathology</i> , 2022, 80, 338-347.	1.6	10
582	The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration. <i>Gastric Cancer</i> , 2021, 24, 1169-1183.	2.7	14
583	Efficacy and Safety of Apatinib for Elderly Patients with Advanced or Metastatic Gastric Cancer After Failure of at Least First-Line Chemotherapy: A Multi-Center, Single-Arm, Phase II Study. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4499-4508.	1.0	5
584	Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 772-798.	0.8	11
585	Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens. <i>Pathology</i> , 2021, 53, 586-594.	0.3	10
586	Quality of life with first-line pembrolizumab for PD-L1â€positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study. <i>ESMO Open</i> , 2021, 6, 100189.	2.0	8
587	B7 score and T cell infiltration stratify immune status in prostate cancer. , 2021, 9, e002455.		16
588	Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4361-4381.	1.0	2
589	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , 2021, 24, 1330-1340.	2.7	7

#	ARTICLE	IF	CITATIONS
590	Glucose metabolic profiles evaluated by PET associated with molecular characteristic landscape of gastric cancer. <i>Gastric Cancer</i> , 2021, , 1.	2.7	2
591	Nutritional Support Indications in Gastroesophageal Cancer Patients: From Perioperative to Palliative Systemic Therapy. A Comprehensive Review of the Last Decade. <i>Nutrients</i> , 2021, 13, 2766.	1.7	22
592	PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. <i>Immunotherapy</i> , 2021, 13, 1053-1065.	1.0	16
593	Comprehensive Characterization of RNA Processing Factors in Gastric Cancer Identifies a Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses. <i>Frontiers in Immunology</i> , 2021, 12, 719628.	2.2	19
594	Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1197-1214.	0.6	4
595	Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer. <i>ESMO Open</i> , 2021, 6, 100179.	2.0	1
596	Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. <i>Annals of Oncology</i> , 2021, 32, 1127-1136.	0.6	34
597	Stemness-related LncRNA pair signature for predicting therapy response in gastric cancer. <i>BMC Cancer</i> , 2021, 21, 1067.	1.1	15
598	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2022, 25, 197-206.	2.7	72
599	Conversion therapy with tislelizumab for high microsatellite instability, unresectable stage III gastric cancer: a case report. <i>Annals of Translational Medicine</i> , 2021, 9, 1489-1489.	0.7	5
600	The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 744889.	1.3	19
601	A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses. <i>Advances in Radiation Oncology</i> , 2022, 7, 100807.	0.6	4
602	Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. <i>Current Treatment Options in Oncology</i> , 2021, 22, 100.	1.3	11
603	Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor Types. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1159-1173.	1.2	7
604	PD-1 inhibitors in esophageal cancer: a systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm. <i>Ecological Management and Restoration</i> , 2022, 35, .	0.2	5
605	Harmaline isolated from <i>Peganum harmala</i> suppresses growth of esophageal squamous cell carcinoma through targeting mTOR. <i>Phytotherapy Research</i> , 2021, 35, 6377-6388.	2.8	7
606	Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the young international society of geriatric oncology. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	0
607	PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Oncology</i> , 2021, 2021, 1-11.	0.6	5

#	ARTICLE	IF	CITATIONS
608	Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 741865.	1.3	6
609	Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. , 2021, 9, e002472.		13
610	A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study. <i>Frontiers in Oncology</i> , 2021, 11, 736620.	1.3	19
611	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e1704-e1729.	1.9	14
612	Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 646355.	1.3	27
613	Integrated Analysis of Stemness-Related LncRNAs Helps Predict the Immunotherapy Responsiveness of Gastric Cancer Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 739509.	1.8	2
614	Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab. <i>Annals of Oncology</i> , 2021, 32, 1618-1625.	0.6	15
615	Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2022, 17, 26-41.	0.8	15
616	Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas. <i>Cancers</i> , 2021, 13, 4919.	1.7	5
617	Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4859-4865.	1.0	2
618	Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101748.	0.7	6
619	Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2240-2249.	1.9	20
620	Combined Therapy of Locally Advanced Oesophageal and Gastroesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. <i>Cancers</i> , 2021, 13, 4591.	1.7	0
621	Identification of an Immune-Related Long Noncoding RNA Pairs Model to Predict Survival and Immune Features in Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 726716.	1.8	6
622	Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 157, 493-510.	1.3	28
623	Genome instability and success of checkpoint inhibitors: form and levels matter. <i>Annals of Oncology</i> , 2021, 32, 1073-1074.	0.6	2
624	PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer. <i>Molecular Therapy</i> , 2022, 30, 621-631.	3.7	17
625	Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. <i>Cancer Letters</i> , 2021, 518, 59-71.	3.2	68

#	ARTICLE	IF	CITATIONS
626	miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer. <i>Cancer Letters</i> , 2021, 518, 115-126.	3.2	34
627	Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature. <i>Cancer Treatment Reviews</i> , 2021, 100, 102289.	3.4	5
628	Advances in clinical immunotherapy for gastric cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188615.	3.3	153
630	Prediction Model for Gastric Cancer With DNA Mismatch Repair Deficiency. <i>Anticancer Research</i> , 2021, 41, 975-982.	0.5	5
631	TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 611444.	1.8	24
632	The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer. <i>Oncolmmunology</i> , 2021, 10, 1938381.	2.1	10
633	Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110295.	1.4	7
634	Current state of chemotherapy and immunotherapy regimens in gastric cancer. , 2021, , 289-316.		0
635	Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
636	Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry. <i>Oncolmmunology</i> , 2021, 10, 1954761.	2.1	28
637	Immune determinants of Barrett's progression to esophageal adenocarcinoma. <i>JCI Insight</i> , 2021, 6, .	2.3	25
638	Immunotherapy in Gastrointestinal Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 93-106.	0.8	7
639	Mechanisms of Resistance to Checkpoint Blockade Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 83-117.	0.8	22
640	Spatiotemporal Changes in Checkpoint Molecule Expression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 167-200.	0.8	5
641	Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Targeted Oncology</i> , 2020, 15, 327-336.	1.7	15
642	The importance of Epstein-Barr virus infection in the systemic treatment of patients with gastric cancer. <i>Seminars in Oncology</i> , 2020, 47, 127-137.	0.8	7
643	M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer. <i>Oncolmmunology</i> , 2021, 10, 1862520.	2.1	26
644	Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial. <i>Oncolmmunology</i> , 2021, 10, 1864908.	2.1	9

#	ARTICLE	IF	CITATIONS
645	PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 748-754.	0.6	7
646	Latency-associated Peptide Identifies Immuno-evasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness. Annals of Surgery, 2022, 275, e163-e173.	2.1	17
648	Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. Cancer Science, 2020, 111, 1943-1957.	1.7	24
649	Targeted therapy for upper gastrointestinal tract cancer: current and future prospects. Histopathology, 2021, 78, 148-161.	1.6	17
650	Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma. Journal of Immunology Research, 2020, 2020, 1-15.	0.9	11
651	Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discovery, 2021, 11, 308-325.	7.7	49
652	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight, 2019, 4, .	2.3	345
653	Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit. JCI Insight, 2020, 5, .	2.3	50
654	Recent advances in the management of gastric adenocarcinoma patients. F1000Research, 2018, 7, 1365.	0.8	26
655	Recent advances in treating oesophageal cancer. F1000Research, 2020, 9, 1189.	0.8	50
656	Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?. World Journal of Clinical Cases, 2019, 7, 1253-1261.	0.3	13
657	Combination of immunotherapy with chemotherapy in first line treatment of metastatic gastric cancer? Too much, too little or just right?. Annals of Translational Medicine, 2020, 8, 1692-1692.	0.7	1
658	When survival curves cross: are we at a crossroads of immunotherapy in gastric cancer?. Annals of Translational Medicine, 2019, 7, S35-S35.	0.7	1
659	Immune checkpoint inhibitors for esophageal cancer: are we moving in the right direction?. Annals of Translational Medicine, 2019, 7, S102-S102.	0.7	7
660	PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study. Translational Cancer Research, 2020, 9, 5315-5322.	0.4	7
661	Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 263-270.	0.7	31
662	Current status of esophageal cancer treatment. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 271-286.	0.7	14
663	Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 287-302.	0.7	20

#	ARTICLE	IF	CITATIONS
664	<p>Current Molecular Targeted Agents for Advanced Gastric Cancer</p>. OncoTargets and Therapy, 2020, Volume 13, 4075-4088.	1.0	17
665	Combined biomarker for prediction of response to an immune checkpoint inhibitor in metastatic gastric cancer. Precision and Future Medicine, 2019, 3, 165-175.	0.5	4
666	Recent Topics and Perspectives on Esophageal Cancer in Japan. JMA Journal, 2018, 1, 30-39.	0.6	7
667	Update on the Treatment of Gastric Cancer. JMA Journal, 2018, 1, 40-49.	0.6	22
668	Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?. Ecancermedalscience, 2020, 14, 1150.	0.6	27
669	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers, 2020, 12, 1303.	1.7	6
670	Oesophageal Adenocarcinomas: Where Do We Stand Today?. Cancers, 2021, 13, 109.	1.7	3
671	Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. World Journal of Gastroenterology, 2018, 24, 2686-2697.	1.4	23
672	Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World Journal of Gastroenterology, 2019, 25, 5773-5788.	1.4	69
673	Significant function and research progress of biomarkers in gastric cancer (Review). Oncology Letters, 2020, 19, 17-29.	0.8	26
674	PD&L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer. Oncology Letters, 2020, 19, 1223-1234.	0.8	12
675	Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress (Review). Oncology Letters, 2020, 20, 46.	0.8	10
676	Tumor immune response and immunotherapy in gastric cancer. Journal of Pathology and Translational Medicine, 2020, 54, 20-33.	0.4	59
677	PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs. Cancer Research and Treatment, 2020, 52, 661-670.	1.3	72
678	A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or <i>POLE</i>-Mutated Metastatic or Unresectable Colorectal Cancer. Cancer Research and Treatment, 2020, 52, 1135-1144.	1.3	43
679	Precision medicine in gastric cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 804-829.	0.8	56
680	Recent progress of chemotherapy and biomarkers for gastroesophageal cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 518-526.	0.8	9
681	Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis. World Journal of Gastrointestinal Oncology, 2020, 12, 1346-1363.	0.8	15

#	ARTICLE	IF	CITATIONS
682	Dealing with the gray zones in the management of gastric cancer: The consensus statement of the Istanbul Group. Turkish Journal of Gastroenterology, 2019, 30, 584-598.	0.4	4
683	Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 855-883.	2.3	672
684	Emerging Multimodality Approaches to Treat Localized Esophageal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1009-1014.	2.3	79
685	Identification of potential biomarkers and their clinical significance in gastric cancer using bioinformatics analysis methods. PeerJ, 2020, 8, e9174.	0.9	4
686	CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients. PeerJ, 2020, 8, e9536.	0.9	19
687	Target Therapy and Immunotherapy in Gastric Cancer. Updates in Surgery Series, 2021, , 225-233.	0.0	0
688	Molecular Evolutionary Process of Advanced Gastric Cancer During Sequential Chemotherapy Detected by Circulating Tumor DNA. SSRN Electronic Journal, 0, , .	0.4	0
689	Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer. Cancer Biology and Medicine, 2022, 19, 1139-1149.	1.4	4
690	Extracellular Matrix-Associated Pathways Promote the Progression of Gastric Cancer by Impacting the Dendritic Cell Axis. International Journal of General Medicine, 2021, Volume 14, 6725-6739.	0.8	5
691	Identification and Validation of an Immune-Related lncRNA Signature to Facilitate Survival Prediction in Gastric Cancer. Frontiers in Oncology, 2021, 11, 666064.	1.3	8
692	Immune cell infiltration signatures identified molecular subtypes and underlying mechanisms in gastric cancer. Npj Genomic Medicine, 2021, 6, 83.	1.7	20
693	Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer. Frontiers in Immunology, 2021, 12, 762120.	2.2	7
694	The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. International Journal of Molecular Sciences, 2021, 22, 10719.	1.8	36
695	Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. Cancers, 2021, 13, 5216.	1.7	15
696	Advances in the curative management of oesophageal cancer. British Journal of Cancer, 2022, 126, 706-717.	2.9	40
697	Risk factors and characteristics of bacterial infection during first-line chemotherapy for metastatic gastric or gastroesophageal junction adenocarcinoma. Supportive Care in Cancer, 2022, 30, 2121-2129.	1.0	0
698	Genomic and Immunologic Markers of Intrinsic Resistance to Pembrolizumab Monotherapy in Microsatellite Instability-High Gastric Cancer: Observations from a Prospective Phase II Study. Global Medical Genetics, 0, , .	0.4	0
699	Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma. Cancers, 2021, 13, 5175.	1.7	10

#	ARTICLE	IF	CITATIONS
700	Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 734323.	1.3	7
701	Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. <i>Cancer Communications</i> , 2021, 41, 1173-1182.	3.7	77
703	Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2022, 34, 95-106.	1.1	9
704	Innovative strategies in metastatic gastric cancer: a short review. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	2
705	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction. <i>Acta Biomedica Scientifica</i> , 2021, 6, 146-159.	0.1	0
706	PROMISING TARGETED THERAPIES GENES AND PROGNOSTIC BIOMARKERS OF GASTRIC CANCER. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2018, 73, 262-272.	0.2	0
707	Study of expression of programmed death ligand 1 and HER2/neu in gastric carcinoma with clinicopathological correlations, in a plan to validate them in immune and targeted therapies. <i>Egyptian Journal of Pathology</i> , 2019, 39, 270.	0.0	0
708	Treatment of Patients with Advanced Gastroesophageal Adenocarcinoma: Does Age Matter?. <i>Drugs and Aging</i> , 2019, 36, 403-409.	1.3	0
709	Understanding Survival Disparities in Gastric Cancer. <i>Oncology & Hematology Review</i> , 2019, 15, 78.	0.2	1
710	Leadership in immuno-oncology network 2 (LION:2) immunotherapy oncology - A present status. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 4, 3-5.	0.0	0
711	Pembrolizumab in advanced gastric cancer: pioneering or prosaic?. <i>Annals of Translational Medicine</i> , 2019, 7, S3-S3.	0.7	1
712	Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab. <i>Cureus</i> , 2019, 11, e4862.	0.2	3
713	<i>Society of Internal Medicine</i> , 2019, 108, 1777-1787.	0.0	0
714	<i>Esophageal and Gastric Cancer</i> . , 2020, , 31-46.		3
715	<i>Systemic Treatment for Metastatic or Recurrent Disease</i> . , 2020, , 275-287.		0
716	Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge. <i>Healthbook TIMES Oncology Hematology</i> , 2019, , 18-21.	0.1	0
717	Primary Gastric Adenosquamous Carcinoma: A Case Report. <i>Gastroenterology Research</i> , 2020, 13, 155-157.	0.4	1
718	Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 3-15.	0.6	3

#	ARTICLE	IF	CITATIONS
719	Multi-layered control of PD-L1 expression in Epstein-Barr virus-associated gastric cancer. <i>Journal of Cancer Metastasis and Treatment</i> , 2020, 2020, .	0.5	3
720	The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma. <i>Cureus</i> , 2020, 12, e8862.	0.2	2
721	Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers. <i>BMC Cancer</i> , 2021, 21, 1167.	1.1	12
722	Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies. <i>Seminars in Diagnostic Pathology</i> , 2022, 39, 48-57.	1.0	1
723	Genome Instability-Related miRNAs Predict Survival, Immune Landscape, and Immunotherapy Responses in Gastric Cancer. <i>Journal of Immunology Research</i> , 2021, 2021, 1-27.	0.9	6
724	TIM3+ cells in gastric cancer: clinical correlates and association with immune context. <i>British Journal of Cancer</i> , 2022, 126, 100-108.	2.9	12
725	Introduction on Cancer Immunology and Immunotherapy. , 2020, , 1-9.		0
726	Identification of ðœregulation of RhoA activity panelðœas a prognostic and predictive biomarker for gastric cancer. <i>Aging</i> , 2021, 13, 714-734.	1.4	1
727	Safety and preliminary signs of efficacy with the combination of pembrolizumab plus oxaliplatin and S-1 in Japanese gastric cancer patients. <i>Annals of Translational Medicine</i> , 2020, 8, 1696-1696.	0.7	0
728	Applications of Antibodies in Therapy, Diagnosis, and Science. <i>Learning Materials in Biosciences</i> , 2021, , 129-159.	0.2	0
729	Therapeutic Vaccines for Gastrointestinal Malignancies. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , 113-158.	0.2	1
730	Emerging Roles of Phytochemicals in the Pathobiology and Management of Esophageal Cancer. , 2020, , 169-187.		0
732	Immunotherapy and Radiosurgery. , 2020, , 423-436.		0
733	A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2021, 10, 56-63.	0.1	5
734	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
736	Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies. <i>Cancer Cell International</i> , 2021, 21, 589.	1.8	17
737	Immunogenomic Landscape and Immune-Related Gene-Based Prognostic Signature in Asian Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 750768.	1.3	6
738	Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 761110.	1.3	5

#	ARTICLE	IF	CITATIONS
739	Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer. <i>World Journal of Clinical Cases</i> , 2021, 9, 9711-9721.	0.3	1
740	State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 451-462.	3.0	2
741	Two distinct phenotypes of immunologically hot gastric cancer subtypes. <i>Biochemistry and Biophysics Reports</i> , 2021, 28, 101167.	0.7	1
744	Management of Locally Advanced Esophageal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 631-646.	0.6	3
745	Siewert III Adenocarcinoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 647-653.	0.6	0
746	Combining Immunotherapy with Multikinase Inhibitors: A Cautious New Promise. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 901-905.	0.1	0
747	Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker. <i>Aging</i> , 2020, 12, 25101-25119.	1.4	7
748	Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitor. <i>American Journal of Cancer Research</i> , 2018, 8, 1689-1696.	1.4	11
749	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. <i>Aging</i> , 2020, 12, 22509-22526.	1.4	4
750	Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 2319-2330.	1.4	3
751	Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors. <i>American Journal of Cancer Research</i> , 2021, 11, 4259-4276.	1.4	1
752	High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. , 2021, 9, e003353.		14
753	Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 2324-2331.	0.7	14
754	The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 712760.	1.3	14
755	ASO Author Reflections: Adjuvant Chemotherapy Should not be Omitted for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability. <i>Annals of Surgical Oncology</i> , 2022, 29, 2332-2333.	0.7	0
756	Immunotherapy for gastric cancer: a 2021 update. <i>Immunotherapy</i> , 2022, 14, 41-64.	1.0	26
757	Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence. <i>Cancers</i> , 2021, 13, 5929.	1.7	8
758	Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 385-400.	1.0	4

#	ARTICLE	IF	CITATIONS
759	Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response. <i>Cureus</i> , 2021, 13, e19739.	0.2	2
760	Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab088.	1.4	2
761	Establishment of a Prognostic Signature of Stromal/Immune-Related Genes for Gastric Adenocarcinoma Based on ESTIMATE Algorithm. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 752023.	1.8	14
762	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives. <i>Cancers</i> , 2021, 13, 5660.	1.7	16
763	Identification of Hypoxia-Related Molecular Classification and Associated Gene Signature in Oral Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 709865.	1.3	1
764	The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 792340.	1.3	3
765	Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 788875.	1.3	6
766	Immunotherapy in Gastrointestinal Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 259-272.	0.8	3
767	A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
768	Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma. <i>Translational Cancer Research</i> , 2022, 11, 193-205.	0.4	10
769	Recent advances in immune-based approaches for the treatment of esophagogastric cancer. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 19-31.	1.0	2
770	Immune evasion mechanisms and therapeutic strategies in gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 216-229.	0.8	7
771	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112516.	2.5	38
772	Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model. <i>Journal of Surgical Research</i> , 2022, 272, 37-50.	0.8	4
773	Oesophageal carcinoma: The prevalence of DNA tumour viruses and therapy. <i>Tumour Virus Research</i> , 2022, 13, 200231.	1.5	6
775	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. <i>Aging</i> , 2020, 12, 22509-22526.	1.4	7
776	Biomarkers for Immunotherapy in Gastrointestinal Cancers. , 2021, , 273-296.		0
777	Stomach: The Standard of Care $\hat{\pm}$ HER2. , 2021, , 75-88.		0

#	ARTICLE	IF	CITATIONS
778	Immunotherapy of Gastric Cancer: Focus on Perioperative Strategies. , 2021, , 59-73.		0
779	Perspective on the Immunotherapy of Gastric Cancer. , 2021, , 89-102.		0
780	PET/CT Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 802257.	1.3	9
781	Antiangiogenic agents in the treatment of colorectal, gastric, and gastroesophageal junction adenocarcinoma. , 2022, , 67-78.		0
782	The B7H4-PDL1 classifier stratifies immuno-phenotype in cervical cancer. <i>Cancer Cell International</i> , 2022, 22, 3.	1.8	2
783	NF- κ B-Related Metabolic Gene Signature Predicts the Prognosis and Immunotherapy Response in Gastric Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-30.	0.9	1
784	Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. <i>Frontiers in Immunology</i> , 2021, 12, 730666.	2.2	31
785	Immunotherapy for Gastroesophageal Tumors: Is There Still Hope for Efficacy?. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	0
786	RBPM2, as a novel biomarker for predicting lymph node metastasis, guides therapeutic regimens in gastric cancer. <i>Human Cell</i> , 2022, 35, 599-612.	1.2	4
787	Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. <i>BMC Cancer</i> , 2022, 22, 22.	1.1	6
788	Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer. <i>PLoS ONE</i> , 2022, 17, e0262455.	1.1	12
789	Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer. <i>Future Oncology</i> , 2022, 18, 139-148.	1.1	1
790	Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 218.	1.7	13
791	The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 802049.	2.2	6
792	Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. <i>BMC Cancer</i> , 2022, 22, 51.	1.1	3
793	Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 806324.	2.2	6
794	Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types. <i>Immunity</i> , 2022, 55, 56-64.e4.	6.6	19
795	A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy. <i>Annals of Translational Medicine</i> , 2022, 10, 102-102.	0.7	4

#	ARTICLE	IF	CITATIONS
796	Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. , 2022, 10, e003091.		67
797	How precision medicine changes medical epistemology: A formative case from Norway. Journal of Evaluation in Clinical Practice, 2022, 28, 1205-1212.	0.9	2
798	Prognostic Ferroptosis-Related lncRNA Signatures Associated With Immunotherapy and Chemotherapy Responses in Patients With Stomach Cancer. Frontiers in Genetics, 2021, 12, 798612.	1.1	23
799	Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion. Frontiers in Immunology, 2021, 12, 783243.	2.2	9
800	Immunotherapy for Esophageal Cancer: State-of-the Art in 2021. Cancers, 2022, 14, 554.	1.7	20
801	Construction and Comprehensive Prognostic Analysis of a Novel Immune-Related lncRNA Signature and Immune Landscape in Gastric Cancer. International Journal of Genomics, 2022, 2022, 1-23.	0.8	3
802	Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures. Frontiers in Immunology, 2022, 13, 805184.	2.2	6
803	Influence of <i>Helicobacter pylori</i> infection on PD-1/PD-L1 blockade therapy needs more attention. Helicobacter, 2022, 27, e12878.	1.6	15
804	PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance. Digestive and Liver Disease, 2022, 54, 1419-1427.	0.4	15
805	Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer. , 2022, 10, e004047.		12
806	Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. Critical Reviews in Oncology/Hematology, 2022, 170, 103597.	2.0	19
807	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
808	Histological Features of Celiac-Disease-like Conditions Related to Immune Checkpoint Inhibitors Therapy: A Signal to Keep in Mind for Pathologists. Diagnostics, 2022, 12, 395.	1.3	2
809	Multimodal treatment in oligometastatic gastric cancer. World Journal of Gastrointestinal Oncology, 2022, 14, 434-449.	0.8	8
810	Understanding the impact of confessional diversity in the Lebanese public sector. Case study: The Lebanese Ministry of Finance. Current Psychology, 2023, 42, 15099-15111.	1.7	1
811	The rapidly evolving landscape of advanced gastric cancer therapy. Future Oncology, 2022, , .	1.1	1
812	Comprehensive analysis of N6-methyladenosine regulators with the tumor immune landscape and correlation between the insulin-like growth factor 2 mRNA-binding protein 3 and programmed death ligand 1 in bladder cancer. Cancer Cell International, 2022, 22, 72.	1.8	8
813	Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 167-192.	2.3	562

#	ARTICLE	IF	CITATIONS
814	Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. <i>Cancer Cell International</i> , 2022, 22, 73.	1.8	21
815	ATRA promotes PD-L1 expression to control gastric cancer immune surveillance. <i>European Journal of Pharmacology</i> , 2022, 920, 174822.	1.7	4
816	Recent insights into the use of immune checkpoint inhibitors in gastric cancer. <i>Porto Biomedical Journal</i> , 2022, 7, e162.	0.4	3
817	Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 193-202.	2.3	4
818	PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. <i>American Journal of Cancer Research</i> , 2021, 11, 5006-5015.	1.4	0
819	DNA methylation markers in esophageal cancer: an emerging tool for cancer surveillance and treatment. <i>American Journal of Cancer Research</i> , 2021, 11, 5644-5658.	1.4	1
820	Approach to Immunotherapy in Oesophageal Cancer. , 2022, , 31-41.		0
821	The dawn of precision medicine in diffuse-type gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210830.	1.4	19
822	Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. <i>Cancer Biology and Therapy</i> , 2022, 23, 191-200.	1.5	10
823	The New Era of Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 1054.	1.7	68
824	Top advances in esophageal/gastroesophageal junction cancers in 2021. <i>Cancer</i> , 2022, 128, 1894-1899.	2.0	1
825	The tumor immune-microenvironment in gastric cancer. <i>Tumori</i> , 2022, 108, 541-551.	0.6	12
826	Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches. <i>Biomedicines</i> , 2022, 10, 543.	1.4	14
827	EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. <i>Nature Communications</i> , 2022, 13, 866.	5.8	51
828	GGT5 Is an Independent Prognostic Biomarker in Stomach Adenocarcinoma. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-14.	0.8	2
829	Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2371-2379.	2.0	4
830	Immunotherapy in Gastric Cancer. <i>Current Oncology</i> , 2022, 29, 1559-1574.	0.9	65
831	Fatty Acid Metabolism and Cancer Immunotherapy. <i>Current Oncology Reports</i> , 2022, 24, 659-670.	1.8	23

#	ARTICLE	IF	CITATIONS
832	Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 267-275.	1.0	4
833	Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery. <i>Molecular Pharmaceutics</i> , 2022, 19, 3530-3541.	2.3	10
834	Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond. <i>Cancers</i> , 2022, 14, 1408.	1.7	2
835	Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. <i>Molecular Cancer</i> , 2022, 21, 86.	7.9	72
836	LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer. <i>Molecular Cancer</i> , 2022, 21, 75.	7.9	54
837	ITGAL as a Prognostic Biomarker Correlated With Immune Infiltrates in Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 808212.	1.8	19
838	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. <i>European Journal of Cancer</i> , 2022, 164, 95-104.	1.3	0
839	Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1583-1595.	1.2	2
840	Carcinosarcoma of the stomach: four cases that expand the morphologic spectrum of gastric cancer with a primitive phenotype. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1051-1062.	1.4	1
841	Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2022, 21, 236-243.	1.0	6
842	Associations of Clinical and Molecular Characteristics with the Response to Immune Checkpoint Blockade in Advanced Gastric Cancers. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	0
843	Interpatient variability in mesothelin expression necessitates its evaluation before gastric cancer immunotherapy. <i>Immunotherapy</i> , 2022, , .	1.0	0
844	The relationship between tumour infiltrating lymphocytes, Epstein-Barr virus and Helicobacter pylori infection in gastric cancer. <i>Ecancermedicalscience</i> , 0, 16, .	0.6	1
845	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 619-628.	2.7	18
846	Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer. <i>BMC Cancer</i> , 2022, 22, 316.	1.1	10
847	Interspatial Distribution of Tumor and Immune Cells in Correlation with PD-L1 in Molecular Subtypes of Gastric Cancers. <i>Cancers</i> , 2022, 14, 1736.	1.7	4
848	Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. , 2022, 10, e004080.		33
849	PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis. <i>Discover Oncology</i> , 2022, 13, 19.	0.8	14

#	ARTICLE	IF	CITATIONS
851	Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. , 2022, 10, e003635.		42
852	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. <i>Chemotherapy</i> , 2023, 68, 1-15.	0.8	0
853	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-â€“Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	0.8	9
854	Identification and Validation of Immune Cells and Hub Genes in Gastric Cancer Microenvironment. <i>Disease Markers</i> , 2022, 2022, 1-18.	0.6	5
855	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44.	2.7	109
856	Predictive biomarkers for the efficacy of nivolumab as a 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. <i>BMC Cancer</i> , 2022, 22, 378.	1.1	16
857	Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients. <i>Clinical Cancer Research</i> , 2022, 28, 2865-2877.	3.2	27
858	Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients. <i>International Immunopharmacology</i> , 2022, 106, 108628.	1.7	1
859	Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. <i>Cancer Discovery</i> , 2022, 12, 984-1001.	7.7	52
860	Gastric cancer: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2021, 23, 541-571.	0.1	2
861	Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy. <i>Cancers</i> , 2022, 14, 106.	1.7	5
862	Gastric Cancer: Applicability and Feasibility of Molecular and Histological Classification in Clinical Practice. <i>Journal of Medical & Radiation Oncology</i> , 2021, 1, 8-26.	0.0	0
863	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. <i>Frontiers in Immunology</i> , 2021, 12, 773168.	2.2	18
865	Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature. <i>BMC Cancer</i> , 2021, 21, 1324.	1.1	8
866	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
867	Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer. <i>Journal of Immunology Research</i> , 2021, 2021, 1-9.	0.9	20
868	Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer. <i>Seminars in Cancer Biology</i> , 2022, 32, 566-582.	4.3	33
869	PD-L1 immunohistochemistry comparison of 22C3 and 28-8 assays for gastric cancer. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2696-2705.	0.6	14

#	ARTICLE	IF	CITATIONS
870	Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival. , 2021, 9, e003580.		20
871	Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal Adenocarcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1324.	1.1	0
872	High ATF4 Expression Is Associated With Poor Prognosis, Amino Acid Metabolism, and Autophagy in Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 740120.	1.3	16
873	Dawning precision treatment for gastric cancer: The latest biomarkers. <i>Journal of Translational Internal Medicine</i> , 2021, 9, 228-230.	1.0	9
874	Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids. <i>Cancers</i> , 2021, 13, 6158.	1.7	17
875	Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE063): A randomized, open-label, phase 3 trial in Asian patients. <i>Cancer</i> , 2022, 128, 995-1003.	2.0	27
876	Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 548-558.	0.6	7
877	Role of Collagen Gel Droplet-Embedded Culture-Drug Sensitivity Testing (CD-DST) for Assessing the Sensitivity of Gastric Cancer to Chemotherapy Drugs Combined with Other Cancer Therapeutic Drugs. <i>Journal of Nippon Medical School</i> , 2022, 89, 412-421.	0.3	2
878	Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients. <i>Frontiers in Immunology</i> , 2022, 13, 783695.	2.2	5
879	Improved immunotherapy for gastric cancer by nanocomposites with capability of triggering Dual-Damage of Nuclear/Mitochondrial DNA and cGAS/STING-Mediated innate immunity. <i>Chemical Engineering Journal</i> , 2022, 443, 136428.	6.6	13
880	Target Therapy and Immunotherapy For Gastric Cancer - Recent Updates. <i>Current Cancer Therapy Reviews</i> , 2022, 18, .	0.2	1
881	Single-Cell Sequencing Identifies the Heterogeneity of CD8+ T Cells and Novel Biomarker Genes in Hepatocellular Carcinoma. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-16.	1.1	7
882	Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers. <i>Frontiers in Immunology</i> , 2022, 13, 810539.	2.2	4
883	Dissecting the Role of Immune Checkpoint Regulation Patterns in Tumor Microenvironment and Prognosis of Gastric Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 853648.	1.1	5
884	PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 93-99.	1.4	6
885	Pembrolizumab for the treatment of advanced esophageal cancer. <i>Future Oncology</i> , 2022, 18, 2311-2319.	1.1	2
886	Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 793403.	1.6	4
887	Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. <i>BMC Medicine</i> , 2022, 20, 133.	2.3	27

#	ARTICLE	IF	CITATIONS
918	Is there still a place for conventional histopathology in the age of molecular medicine? LaurÃ©n classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis. <i>Histology and Histopathology</i> , 2021, 36, 587-613.	0.5	8
919	Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer. <i>In Vivo</i> , 2022, 36, 1126-1135.	0.6	9
920	A Risk Model of Eight Immune-Related Genes Predicting Prognostic Response to Immune Therapies for Gastric Cancer. <i>Genes</i> , 2022, 13, 720.	1.0	3
921	Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 856444.	1.3	3
922	Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinomaâ€”A Case Series of Non-Operative Long-Term Survivors. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 24.	1.0	0
924	Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , .	1.2	4
925	Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. <i>Nature Medicine</i> , 2022, 28, 1189-1198.	15.2	190
926	Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). <i>BMC Cancer</i> , 2022, 22, 537.	1.1	14
927	A peptide-AIEgen nanocomposite mediated whole cancer immunity cycle-cascade amplification for improved immunotherapy of tumor. <i>Biomaterials</i> , 2022, 285, 121528.	5.7	21
928	A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. <i>European Journal of Cancer</i> , 2022, 169, 93-102.	1.3	30
929	Molecular pathogenesis and emerging targets of gastric adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 1079-1095.	0.8	6
930	Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response. <i>Pharmaceuticals</i> , 2022, 15, 605.	1.7	0
931	Genomic landscape of microsatellite instability in Chinese tumors: A comparison of Chinese and <sc>TCGA</sc> cohorts. <i>International Journal of Cancer</i> , 2022, 151, 1382-1393.	2.3	9
932	Research Status of Neoadjuvant Therapy for Locally Advanced Gastric Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 4028-4032.	0.0	0
933	Trametes robiniophila Murr Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Modulating Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	4
934	Combination of CRAFTY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.. <i>American Journal of Cancer Research</i> , 2022, 12, 1899-1911.	1.4	0
935	Association of SII and PNI with Efficacy and Prognosis of Immune Checkpoint Inhibitors in Patients with Advanced Gastric Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 4295-4302.	0.0	1
936	Research Progress and Future Treatment of Advanced Gastric Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 4523-4529.	0.0	0

#	ARTICLE	IF	CITATIONS
937	Microsatellite instability and chemosensitivity in solid tumours. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210993.	1.4	8
938	PD-L1 expression and overall survival in Asian and western patients with gastric cancer. <i>Future Oncology</i> , 2022, 18, 2623-2634.	1.1	2
939	Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers. <i>Gut and Liver</i> , 2022, , .	1.4	6
940	Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	9
941	TGF β 2-Associated Signature Predicts Prognosis and Tumor Microenvironment Infiltration Characterization in Gastric Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	1
942	Construction of ovarian metastasis-related immune signature predicting prognosis of gastric cancer patients. <i>Cancer Medicine</i> , 2023, 12, 913-929.	1.3	5
943	A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen. <i>Medical Oncology</i> , 2022, 39, .	1.2	0
944	The Incidence-Based Mortality and Survival Trends in Patients with Gastric Signet Ring Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-7.	0.6	0
945	The current management and biomarkers of immunotherapy in advanced gastric cancer. <i>Medicine (United States)</i> , 2022, 101, e29304.	0.4	16
946	Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. <i>Cancers</i> , 2022, 14, 2758.	1.7	5
947	Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. <i>Gastric Cancer</i> , 2022, 25, 741-750.	2.7	42
948	The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
949	Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: Elements of a recipe for disaster. <i>Cytokine</i> , 2022, 156, 155917.	1.4	1
950	Treatment heterogeneity and overall survival in patients with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma in the United States. <i>Journal of Gastrointestinal Oncology</i> , 2021, .	0.6	3
951	Selection of RNA-based evaluation methods for tumor microenvironment by comparing with histochemical and flow cytometric analyses in gastric cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
952	Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial. <i>Cancer Management and Research</i> , 0, Volume 14, 2007-2015.	0.9	6
953	Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes. <i>ACS Chemical Biology</i> , 2022, 17, 1876-1889.	1.6	11
954	Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 1-17.	1.4	3

#	ARTICLE	IF	CITATIONS
955	Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6664.	1.8	13
956	The current state of molecular profiling in gastrointestinal malignancies. <i>Biology Direct</i> , 2022, 17, .	1.9	5
957	Prevalence of Epstein–Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-11.	0.9	2
958	Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer. , 2022, 10, e004703.		11
959	Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 6184-6191.	0.3	1
960	Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial). <i>Future Oncology</i> , 2022, 18, 2495-2503.	1.1	1
961	A Novel Algorithm for Detecting Microsatellite Instability Based on Next-Generation Sequencing Data. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
962	Efficacy and Safety of Camrelizumab in Combination with Docetaxel+S-1 Sequenced by Camrelizumab+S-1 for Stage III (PD-1+/MSI-H/EBV+/dMMR) Gastric Cancer: Study Protocol for a Single-Center, Prospective, Open-Label, Single-Arm Trial. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	2
963	Immune checkpoint inhibitors™ combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	4
964	Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
965	Programmed death-ligand 1 expression in the immune compartment of colon carcinoma. <i>Modern Pathology</i> , 0, , .	2.9	2
966	Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma. <i>Digestive and Liver Disease</i> , 2023, 55, 276-282.	0.4	1
967	An Immune Signature for Risk Stratification and Therapeutic Prediction in Helicobacter pylori-Infected Gastric Cancer. <i>Cancers</i> , 2022, 14, 3276.	1.7	6
968	Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. <i>BMC Medicine</i> , 2022, 20, .	2.3	30
969	Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter. <i>Updates in Surgery</i> , 2023, 75, 291-303.	0.9	5
970	Immune-Related LncRNAs to Construct a Prognosis Risk-Assessment Model for Gastric Cancer. <i>Current Oncology</i> , 2022, 29, 4923-4935.	0.9	4
971	SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	2
972	Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	27

#	ARTICLE	IF	CITATIONS
973	Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
974	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. <i>Clinical Cancer Research</i> , 2022, 28, 3489-3498.	3.2	35
975	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	1.1	6
976	Research progress in targeted therapy and immunotherapy for gastric cancer. <i>Chinese Medical Journal</i> , 2022, 135, 1299-1313.	0.9	7
977	Advances in immunotherapy for metastatic esophageal cancer. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 7, 69-76.	0.0	0
978	Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
979	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13
980	Genomic Analysis Uncovers the Prognostic and Immunogenetic Feature of Pyroptosis in Gastric Carcinoma: Indication for Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
981	The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma. <i>Gastric Cancer</i> , 2022, 25, 943-955.	2.7	5
982	PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
983	The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 169-181.	2.0	9
984	Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice. <i>Journal of Clinical Oncology</i> , 2022, 40, 2751-2762.	0.8	27
985	Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. <i>European Journal of Cancer</i> , 2022, 172, 387-399.	1.3	4
986	Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma. <i>Oncologist</i> , 2022, 27, e856-e869.	1.9	5
987	T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. <i>Future Oncology</i> , 2022, 18, 2783-2790.	1.1	2
988	A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
989	Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System. <i>Biomedicines</i> , 2022, 10, 1842.	1.4	5
990	Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20

#	ARTICLE	IF	CITATIONS
991	Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3736.	1.7	7
992	Classification of stomach adenocarcinoma based on fatty acid metabolism-related genes profiling. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	3
993	High interobserver and intraobserver reproducibility among pathologists assessing <scp>PD-L1 CPS</scp> across multiple indications. <i>Histopathology</i> , 2022, 81, 732-741.	1.6	9
994	Carcinoma of unknown primary: Molecular tumor board-based therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 510-523.	157.7	2
995	Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188775.	3.3	12
996	Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	3
997	Neoadjuvant and Adjuvant Therapy Approaches to Gastric Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1247-1268.	1.3	19
998	Impact of intratumoural <scp>CD96</scp> expression on clinical outcome and therapeutic benefit in gastric cancer. <i>Cancer Science</i> , 2022, 113, 4070-4081.	1.7	7
999	Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. <i>ESMO Open</i> , 2022, 7, 100563.	2.0	15
1000	Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors. <i>Pathology Research and Practice</i> , 2022, 238, 154110.	1.0	1
1001	Phase Ib study of eprentapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. <i>ESMO Open</i> , 2022, 7, 100573.	2.0	16
1002	A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options. <i>Experimental and Molecular Pathology</i> , 2022, 128, 104832.	0.9	11
1003	Diagnostic Applications of Nuclear Medicine: Gastric Cancers. , 2022, , 1-18.		0
1004	Advances in Treatment Models of Advanced Gastric Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210903.	0.8	2
1005	Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1006	Available Immunotherapy Drugs in Oncology. <i>Current Clinical Pathology</i> , 2022, , 5-23.	0.0	0
1007	Diagnostic Applications of Nuclear Medicine: Gastric Cancers. , 2022, , 829-846.		0
1008	European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211188.	1.4	1

#	ARTICLE	IF	CITATIONS
1009	A narrative review of the evolving role of immunotherapy in the management of esophageal and gastric cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2007-2019.	0.6	2
1010	Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	25
1011	Intratumoral CD8+ T cells as a potential positive predictor of chemoimmunotherapy response in PD-L1-negative advanced gastric cancer patients: a retrospective cohort study. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1668-1678.	0.6	3
1012	Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. <i>Cancers</i> , 2022, 14, 4201.	1.7	1
1013	Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done. <i>Current Oncology</i> , 2022, 29, 6433-6444.	0.9	1
1014	DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma. <i>Aging</i> , 2022, 14, 7824-7850.	1.4	1
1015	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1016	Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 4670.	1.7	4
1017	ELEVATE â€“ evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
1018	Long-term survival after immunotherapy and targeted therapy without chemotherapy in an elderly patient with HER2-positive gastroesophageal junction cancer: A case report. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	2
1019	Advances in the management of peritoneal malignancies. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 698-718.	12.5	20
1020	Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer. <i>Oncologist</i> , 0, , .	1.9	0
1021	Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
1022	Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1024	Therapeutic strategies for gastric cancer targeting immune cells: Future directions. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1025	Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1026	Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report. <i>Current Oncology</i> , 2022, 29, 6334-6341.	0.9	1
1028	EBV and further emerging directions towards increased precision in gastric cancer treatment. <i>Translational Cancer Research</i> , 2022, 11, 3012-3014.	0.4	0

#	ARTICLE	IF	CITATIONS
1029	Does immunotherapy change the treatment paradigm in metastatic gastric cancer?. , 2022, 39, .		2
1030	Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 679-688.	1.6	3
1032	Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1033	DKK1 Promotes Tumor Immune Evasion and Impedes Anti-“PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 1506-1524.	1.6	21
1035	Immune Checkpoint Inhibitors in Gastroesophageal Junction or Gastric Cancer. , 2022, , 1-25.		0
1036	Molecular Pathology of Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2022, 22, 264.	0.9	6
1037	Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2072-2081.	0.6	3
1038	Novel insight into the role of immunotherapy in gastrointestinal cancer (Review). <i>Molecular and Clinical Oncology</i> , 2022, 17, .	0.4	1
1039	Identification of N7-methylguanosine related subtypes and construction of prognostic model in gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1040	Adenocarcinoma de la uniÃ³n gastroesofÃ¡gica metastÃ¡sico con dÃ©ficit de expresiÃ³n de proteÃ­nas de reparaciÃ³n del ADN. , 2022, 26, .		0
1041	EBV-associated diseases: Current therapeutics and emerging technologies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
1042	Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis. <i>Journal of Immunotherapy</i> , 2023, 46, 43-55.	1.2	4
1043	Tumor Microenvironment, Clinical Features, and Advances in Therapy for Bone Metastasis in Gastric Cancer. <i>Cancers</i> , 2022, 14, 4888.	1.7	7
1044	Comprehensive Molecular Analyses of an SLC Family-Based Model in Stomach Adenocarcinoma. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	1
1046	Bifunctional anti-PD-L1/TGF-Î²RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. <i>BMC Medicine</i> , 2022, 20, .	2.3	16
1047	Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer. <i>Oncolmmunology</i> , 2022, 11, .	2.1	17
1048	The Role of Interleukin-7 in the Formation of Tertiary Lymphoid Structures and Their Prognostic Value in Gastrointestinal Cancers. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 105-117.	0.6	1
1049	Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
1050	Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience. <i>Cancer Management and Research</i> , 0, Volume 14, 3083-3094.	0.9	2
1051	Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1183-1196.	1.0	8
1052	Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan. <i>Gastric Cancer</i> , 2023, 26, 132-144.	2.7	2
1053	Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer. <i>Thoracic Surgery Clinics</i> , 2022, 32, 467-478.	0.4	2
1054	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. <i>PLoS ONE</i> , 2022, 17, e0272022.	1.1	4
1055	A nomogram model based on the number of examined lymph nodesâ€“related signature to predict prognosis and guide clinical therapy in gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1056	Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 102031.	0.7	2
1057	Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. <i>Current Opinion in Neurology</i> , 2022, 35, 803-813.	1.8	7
1058	The full management from first-line to third-line treatments in patients with Her-2â€“negative advanced gastric cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1059	Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer. <i>Cancers</i> , 2022, 14, 5615.	1.7	8
1060	Quantitative Radiological Features and Deep Learning for the Non-Invasive Evaluation of Programmed Death Ligand 1 Expression Levels in Gastric Cancer Patients: A Digital Biopsy Study. <i>Academic Radiology</i> , 2023, 30, 1317-1328.	1.3	4
1061	High-level of intratumoral GTR+ CD4 T cells associate with poor prognosis in gastric cancer. <i>IScience</i> , 2022, 25, 105529.	1.9	4
1062	A SERPINE1-Based Immune Gene Signature Predicts Prognosis and Immunotherapy Response in Gastric Cancer. <i>Pharmaceuticals</i> , 2022, 15, 1401.	1.7	2
1063	The prognostic impact of the immune microenvironment in small-cell neuroendocrine carcinoma of the uterine cervix: PD-L1 and immune cell subtypes. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3
1064	Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1065	Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
1066	Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer. <i>Journal of Advanced Research</i> , 2023, 51, 121-134.	4.4	14
1068	Current developments in gastric cancer: from molecular profiling to treatment strategy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 155-170.	8.2	61

#	ARTICLE	IF	CITATIONS
1069	<sc>KCNQ1OT1</sc> sponges <sc>miR</sc>â€³4a to promote malignant progression of malignant melanoma via upregulation of the <sc>STAT3</sc>/<sc>PDâ€¹1</sc> axis. Environmental Toxicology, 2023, 38, 368-380.	2.1	6
1070	Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images. Computers in Biology and Medicine, 2023, 152, 106337.	3.9	7
1071	Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumabâ€“ipilimumab in metastatic gastric and esophageal cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211427.	1.4	1
1072	Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression. Journal of Nutritional Biochemistry, 2023, 112, 109226.	1.9	2
1073	Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinformatics Analysis and Clinicopathological Evidence. International Journal of Medical Sciences, 2022, 19, 1977-1988.	1.1	1
1074	Targets, Therapies and the Role of Serial Biopsies for Prognostication and Assessing Changes to Tumour Biology in Oesophageal and Oesophagogastric Junction Cancers. Touch Reviews in Oncology & Haematology, 2022, 18, 107.	0.1	0
1075	Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review. JCO Oncology Practice, 2023, 19, 107-115.	1.4	7
1076	Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review. Frontiers in Oncology, 0, 12, .	1.3	2
1077	Near-infrared-dye labeled tumor vascular-targeted dimer GEBP11 peptide for image-guided surgery in gastric cancer. Frontiers in Oncology, 0, 12, .	1.3	0
1078	PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer. Frontiers in Immunology, 0, 13, .	2.2	9
1079	<i>ACTA2</i> Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer. Clinical Cancer Research, 2023, 29, 1077-1085.	3.2	9
1081	Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells. , 2022, 10, e005200.		0
1082	The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Frontiers in Molecular Biosciences, 0, 9, .	1.6	4
1083	Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia. Gastric Cancer, 2023, 26, 220-233.	2.7	2
1084	Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062. Japanese Journal of Clinical Oncology, 2023, 53, 221-229.	0.6	1
1085	Pembrolizumab versus paclitaxel for previously treated, advanced gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized clinical trials. Medicine (United States), 2022, 101, e31940.	0.4	0
1086	Correlation between immuneâ€“related adverse events and treatment efficacy of antiâ€“PD1 immunotherapy in patients with esophageal squamous cell carcinoma. Oncology Letters, 2022, 25, .	0.8	3
1087	Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. Diagnostics, 2022, 12, 3157.	1.3	6

#	ARTICLE	IF	CITATIONS
1088	Immune-based combination therapy for esophageal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1089	The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
1090	Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1091	Personalized immune subtypes based on machine learning predict response to checkpoint blockade in gastric cancer. <i>Briefings in Bioinformatics</i> , 0, , .	3.2	0
1093	Effectiveness and safety of anti-PD-1 monotherapy or combination therapy in Chinese advanced gastric cancer: A real-world study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1094	Physical Function and Nutrition in Patients with Esophageal Cancer and Head and Neck Cancer. , 2022, , 461-491.		0
1095	Comprehensive Analysis of Clinicopathological and Molecular Features to Predict Anti-PD-1-Based Therapy Efficacy in Patients with Advanced Gastric Signet Ring Cell Carcinoma. <i>Journal of Personalized Medicine</i> , 2023, 13, 115.	1.1	0
1096	A phase II study of perioperative treatment in gastric cancer with No.16a2/b1 lymph node metastasis: DRAGON-06 trial. <i>Future Oncology</i> , 0, , .	1.1	0
1097	High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382211505.	0.8	1
1098	A high interferon gamma signature of CD8+ T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1099	Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, 175628482211482.	1.4	1
1100	Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma. <i>PeerJ</i> , 0, 11, e14691.	0.9	1
1101	Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: A retrospective real-world study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1102	Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma. <i>Pharmaceuticals</i> , 2023, 16, 102.	1.7	0
1103	A standardized pathology report for gastric cancer: 2nd edition. <i>Journal of Pathology and Translational Medicine</i> , 2023, 57, 1-27.	0.4	4
1104	Identification and validation of a PD-L1-related signature from mass spectrometry in gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
1105	Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
1106	CT-based delta radiomics in predicting the prognosis of stage IV gastric cancer to immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
1107	Peripheral and tumor-infiltrating immune cells are correlated with patient outcomes in ovarian cancer. <i>Cancer Medicine</i> , 2023, 12, 10045-10061.	1.3	1
1108	Application of immune checkpoint inhibitors in immunotherapy for gastric cancer. <i>Immunotherapy</i> , 2023, 15, 101-115.	1.0	2
1109	Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. <i>ESMO Open</i> , 2023, 8, 100762.	2.0	30
1110	Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group. <i>Cancers</i> , 2023, 15, 244.	1.7	3
1111	The Role of Immune Checkpoint Inhibitors in Cancer Therapy. <i>Clinics and Practice</i> , 2023, 13, 22-40.	0.6	14
1112	Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2874-2884.	0.6	2
1113	Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 3300-3313.	0.6	2
1114	The loss of epithelial Smad4 drives immune evasion via CXCL1 while displaying vulnerability to combinatorial immunotherapy in gastric cancer. <i>Cell Reports</i> , 2022, 41, 111878.	2.9	5
1115	Baseline splenic volume as a biomarker for clinical outcome and circulating lymphocyte count in gastric cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1116	Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach. <i>Journal of Gastric Cancer</i> , 2023, 23, 3.	0.9	66
1117	Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial). <i>Journal of Thoracic Disease</i> , 2023, .	0.6	1
1118	Tumor immunology. , 2023, , 245-452.		0
1119	Recent Progress in Immunotherapy for Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2023, 23, 207.	0.9	7
1120	Predictive significance of surgery-induced lymphopenia on the survival after curative resection for locally advanced gastric cancer: a retrospective cohort analysis. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	2
1121	Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. <i>Cell Reports Medicine</i> , 2023, 4, 100916.	3.3	10
1123	<sc>PD-1</sc> expression by different scoring methods and different cutoff values and correlation with clinicopathological characteristics in gastric cancer: A retrospective study. <i>Precision Medical Sciences</i> , 0, , .	0.1	0
1124	A Standardized Pathology Report for Gastric Cancer: 2nd Edition. <i>Journal of Gastric Cancer</i> , 2023, 23, 107.	0.9	4
1125	Introduction on Cancer Immunotherapy. , 2023, , 1-27.		0

#	ARTICLE	IF	CITATIONS
1126	Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. <i>Life Sciences</i> , 2023, 318, 121459.	2.0	6
1127	Liquid biopsy and immunotherapy: is all that glitter gold?. , 2023, , 83-117.		0
1128	Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination. <i>Journal of Gastric Cancer</i> , 0, 23, .	0.9	3
1129	INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). <i>BMC Cancer</i> , 2023, 23, .	1.1	3
1130	Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	0.6	0
1132	Updated Immunotherapy for Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 2636.	1.0	6
1133	Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1134	Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer. <i>Modern Pathology</i> , 2023, 36, 100128.	2.9	7
1135	Combining of immunotherapeutic approaches with chemotherapy for treatment of gastric cancer: Achievements and limitations. <i>International Immunopharmacology</i> , 2023, 118, 110062.	1.7	6
1136	Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study. <i>Translational Oncology</i> , 2023, 31, 101657.	1.7	2
1137	POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6849.	1.8	4
1139	Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. , 2022, , 1-34.		0
1140	PD-1 expression in gastric and gastroesophageal junction cancer patients treated with perioperative chemotherapy. <i>Journal of Surgical Oncology</i> , 2022, 126, 150-160.	0.8	2
1141	Mismatch Repair Status Characterization as an Immune-Related Biomarker in Oncology. , 2023, , 1-21.		0
1142	Pathologische Grundlagen und Anforderungen. , 2022, , 25-58.		0
1143	Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States. <i>Current Oncology</i> , 2023, 30, 1869-1881.	0.9	2
1144	Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3316.	1.8	7
1145	Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma. <i>Annals of Surgery</i> , 2023, 278, e511-e518.	2.1	2

#	ARTICLE	IF	CITATIONS
1146	Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 352-367.	0.8	0
1147	Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab. <i>Cancer Medicine</i> , 0, , .	1.3	1
1148	Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2023, 30, 3594-3602.	0.7	3
1149	Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	4
1150	Complement receptor <sc>C5aR1</sc> blockade reprograms tumor-associated macrophages and synergizes with <sc>anti-PD</sc> therapy in gastric cancer. <i>International Journal of Cancer</i> , 2023, 153, 224-237.	2.3	5
1151	Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1152	Elevated PD-L1 Expression and Microsatellite Instability in Elderly Patients With Gastric Cancer. <i>Journal of Immunotherapy</i> , 2023, 46, 111-119.	1.2	1
1153	Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis. <i>PLoS ONE</i> , 2023, 18, e0282017.	1.1	3
1154	A Case of Pembrolizumab-Induced Diabetic Ketoacidosis and Hyperthyroidism in a Patient With Recurrent Esophageal Adenocarcinoma. <i>Cureus</i> , 2023, , .	0.2	1
1155	Xiaotan Sanjie decoction normalizes tumor permissive microenvironment in gastric cancer (Review). <i>Oncology Reports</i> , 2023, 49, .	1.2	2
1156	Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1157	Sintilimab Plus Apatinib and Chemotherapy as Second/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
1158	Progression in immunotherapy for advanced prostate cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
1159	A noninvasive nomogram model based on CT features to predict DNA mismatch repair deficiency in gastric cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1161	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
1162	Single-Cell Profiling of Tumor Immune Microenvironment Reveals Immune Irresponsiveness in Gastric Signet-Ring Cell Carcinoma. <i>Gastroenterology</i> , 2023, 165, 88-103.	0.6	13
1163	High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma. <i>Modern Pathology</i> , 2023, 36, 100154.	2.9	8
1164	Recent advances in immunotherapy and molecular targeted therapy for gastric cancer. <i>Future Science OA</i> , 2023, 9, .	0.9	2

#	ARTICLE	IF	CITATIONS
1165	Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. <i>Cancer Management and Research</i> , 0, Volume 15, 265-275.	0.9	0
1166	Definition of a Novel Immunogenic Cell Death-Relevant Gene Signature Associated with Immune Landscape in Gastric Cancer. <i>Biochemical Genetics</i> , 2023, 61, 2092-2115.	0.8	2
1167	Immunotherapy in Gastrointestinal Malignancies. , 2023, , 1-23.		0
1168	Current trends in perioperative treatment of resectable gastric cancer. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 323-337.	0.8	0
1170	Tumor Immunophenotypingâ€Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer. <i>Advanced Science</i> , 2023, 10, .	5.6	3
1171	New Progress of Immunotherapy in Gastric Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 4904-4911.	0.0	0
1172	<scp>PDâ€1</scp> expression downregulation by <scp>RNF43</scp> in gastric carcinoma enhances antitumour activity of T cells. <i>Scandinavian Journal of Immunology</i> , 0, , .	1.3	0
1173	A Retrospective Cohort Study Examining the Effects of Antiâ€PDâ€1 Antibody in Combination with Apatinib in Patients Previously Treated for Her2â€Negative Advanced Gastric/Gastroesophageal Junction Cancer. <i>Journal of Clinical Pharmacology</i> , 2023, 63, 769-775.	1.0	3
1174	Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	4
1175	Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases. , 2023, 11, e006280.		5
1176	Immune Responses to Solid Tumors and Immune Checkpoint Therapy. , 2023, , 1028-1041.		0
1177	Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway. <i>Clinical and Translational Oncology</i> , 2023, 25, 3122-3138.	1.2	1
1178	Research Progress of Immunotherapy for Gastric Cancer. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382211505.	0.8	2
1179	Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?. <i>Cancers</i> , 2023, 15, 2273.	1.7	2
1180	HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective. <i>Journal of Clinical Pathology</i> , 2023, 76, 815-821.	1.0	3
1181	IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1182	Treatment Status and Progress of Advanced Gastric Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 5419-5426.	0.0	0
1183	Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients. <i>Pathology and Oncology Research</i> , 0, 29, .	0.9	0

#	ARTICLE	IF	CITATIONS
1184	Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
1185	Immunotherapy and Cancer Stem Cells. , 2023, , 165-235.		0
1215	Probiotics Based Anticancer Immunity In Stomach Cancer. , 2023, , 162-188.		0
1221	Overview of Treatment. , 2023, , 99-103.		0
1222	Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1289	Immunotherapy in Esophageal Cancer. , 2023, , 99-111.		0
1304	Immunotherapy in Esophagogastric Cancer: Treatment Landscape, Challenges, and New Directions. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	0.6	0
1305	Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	0.6	0
1308	Fatty acid metabolism of immune cells: a new target of tumour immunotherapy. <i>Cell Death Discovery</i> , 2024, 10, .	2.0	1
1326	Special Type of Surgical Resection for Gastric Cancer. , 2023, , 41-113.		0
1327	Potential Role of Nrf2, HER2, and ALDH in Cancer Stem Cells: A Narrative Review. <i>Journal of Membrane Biology</i> , 2024, 257, 3-16.	1.0	0